<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Pers Med</journal-id><journal-id journal-id-type="iso-abbrev">J Pers Med</journal-id><journal-id journal-id-type="pmc-domain-id">2605</journal-id><journal-id journal-id-type="pmc-domain">jpersmed</journal-id><journal-id journal-id-type="publisher-id">jpm</journal-id><journal-title-group><journal-title>Journal of Personalized Medicine</journal-title></journal-title-group><issn pub-type="epub">2075-4426</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11355139</article-id><article-id pub-id-type="pmcid-ver">PMC11355139.1</article-id><article-id pub-id-type="pmcaid">11355139</article-id><article-id pub-id-type="pmcaiid">11355139</article-id><article-id pub-id-type="pmid">39202054</article-id><article-id pub-id-type="doi">10.3390/jpm14080863</article-id><article-id pub-id-type="publisher-id">jpm-14-00863</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Targeted Screening for Cancer: Learnings and Applicability to Melanoma: A Scoping Review</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0004-6631-9361</contrib-id><name name-style="western"><surname>Zheng</surname><given-names initials="L">Lejie</given-names></name><xref rid="af1-jpm-14-00863" ref-type="aff">1</xref><xref rid="fn1-jpm-14-00863" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-5712-220X</contrib-id><name name-style="western"><surname>Smit</surname><given-names initials="AK">Amelia K.</given-names></name><xref rid="af2-jpm-14-00863" ref-type="aff">2</xref><xref rid="af3-jpm-14-00863" ref-type="aff">3</xref><xref rid="fn1-jpm-14-00863" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5331-6370</contrib-id><name name-style="western"><surname>Cust</surname><given-names initials="AE">Anne E.</given-names></name><xref rid="af2-jpm-14-00863" ref-type="aff">2</xref><xref rid="af3-jpm-14-00863" ref-type="aff">3</xref><xref rid="fn2-jpm-14-00863" ref-type="author-notes">&#8225;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1728-8085</contrib-id><name name-style="western"><surname>Janda</surname><given-names initials="M">Monika</given-names></name><xref rid="af1-jpm-14-00863" ref-type="aff">1</xref><xref rid="c1-jpm-14-00863" ref-type="corresp">*</xref><xref rid="fn2-jpm-14-00863" ref-type="author-notes">&#8225;</xref></contrib></contrib-group><aff id="af1-jpm-14-00863"><label>1</label>Centre for Health Services Research, The University of Queensland, St. Lucia, QLD 4067, Australia; <email>lejie.zheng@uq.edu.au</email></aff><aff id="af2-jpm-14-00863"><label>2</label>The Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, NSW 2006, Australia; <email>amelia.smit@sydney.edu.au</email> (A.K.S.); <email>anne.cust@sydney.edu.au</email> (A.E.C.)</aff><aff id="af3-jpm-14-00863"><label>3</label>Melanoma Institute Australia, The University of Sydney, Sydney, NSW 2065, Australia</aff><author-notes><corresp id="c1-jpm-14-00863"><label>*</label>Correspondence: <email>m.janda@uq.edu.au</email></corresp><fn id="fn1-jpm-14-00863"><label>&#8224;</label><p>Co-first authors.</p></fn><fn id="fn2-jpm-14-00863"><label>&#8225;</label><p>Co-senior authors.</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>8</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2024</year></pub-date><volume>14</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">469548</issue-id><elocation-id>863</elocation-id><history><date date-type="received"><day>02</day><month>7</month><year>2024</year></date><date date-type="rev-recd"><day>12</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>08</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>29</day><month>08</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-08-12 15:25:29.243"><day>12</day><month>08</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jpm-14-00863.pdf"/><abstract><p>This scoping review aims to systematically gather evidence from personalized cancer-screening studies across various cancers, summarize key components and outcomes, and provide implications for a future personalized melanoma-screening strategy. Peer-reviewed articles and clinical trial databases were searched for, with restrictions on language and publication date. Sixteen distinct studies were identified and included in this review. The studies&#8217; results were synthesized according to key components, including risk assessment, risk thresholds, screening pathways, and primary outcomes of interest. Studies most frequently reported about breast cancers (<italic toggle="yes">n</italic> = 7), followed by colorectal (<italic toggle="yes">n</italic> = 5), prostate (<italic toggle="yes">n</italic> = 2), lung (<italic toggle="yes">n</italic> = 1), and ovarian cancers (<italic toggle="yes">n</italic> = 1). The identified screening programs were evaluated predominately in Europe (<italic toggle="yes">n</italic> = 6) and North America (<italic toggle="yes">n</italic> = 4). The studies employed multiple different risk assessment tools, screening schedules, and outcome measurements, with few consistent approaches identified across the studies. The benefit&#8211;harm assessment of each proposed personalized screening program indicated that the majority were feasible and effective. The establishment of a personalized screening program is complex, but results of the reviewed studies indicate that it is feasible, can improve participation rates, and screening outcomes. While the review primarily examines screening programs for cancers other than melanoma, the insights can be used to inform the development of a personalized melanoma screening strategy.</p></abstract><kwd-group><kwd>personalized screening</kwd><kwd>cancer prevention</kwd><kwd>melanoma</kwd><kwd>scoping review</kwd></kwd-group><funding-group><award-group><funding-source>NHMRC</funding-source><award-id>2009923</award-id><award-id>2008454</award-id><award-id>2006551</award-id></award-group><award-group><funding-source>University of Queensland</funding-source></award-group><funding-statement>Amelia K. Smit is supported by a NHMRC Synergy grant (#2009923). Anne E. Cust is supported by a NHMRC Investigator Grant (#2008454). Monika Janda is supported by NHMRC CRE grant (#2006551) and NHMRC Synergy grant (#2009923) Lejie Zheng is supported by RTP Scholarship from the University of Queensland.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-jpm-14-00863"><title>1. Introduction</title><p>Cancer was responsible for nearly one-sixth of global mortality, with an estimated 10 million deaths occurring in 2020 [<xref rid="B1-jpm-14-00863" ref-type="bibr">1</xref>]. Early cancer detection through population-based screening programs has already resulted in significant improvements in survival rates for several cancers, including breast, cervical, and colorectal [<xref rid="B2-jpm-14-00863" ref-type="bibr">2</xref>]. Although there are many benefits for reducing cancer incidence and mortality, population-based cancer-screening programs are also resource-intensive and may lead to overdiagnosis. This phenomenon pertains to individuals who, if left untreated, would not have been impacted by the detected cancer [<xref rid="B3-jpm-14-00863" ref-type="bibr">3</xref>]. Overtreatment has also been reported as a result of false positive screening examinations [<xref rid="B4-jpm-14-00863" ref-type="bibr">4</xref>,<xref rid="B5-jpm-14-00863" ref-type="bibr">5</xref>]. Currently, most organized cancer-screening programs are based on fixed eligibility requirements such as age and sex. In a shift away from the &#8216;one size fits all&#8217; approach, interest in personalized screening is growing [<xref rid="B6-jpm-14-00863" ref-type="bibr">6</xref>,<xref rid="B7-jpm-14-00863" ref-type="bibr">7</xref>].</p><p>Personalized screening approaches take into account individuals&#8217; risk-factors to assess eligibility and determine screening frequency, such as genetic risk, family history and lifestyle factors [<xref rid="B8-jpm-14-00863" ref-type="bibr">8</xref>,<xref rid="B9-jpm-14-00863" ref-type="bibr">9</xref>]. One recent example is a lung-cancer-screening trial conducted in the United States, which was introduced only for people who have a strong smoking history [<xref rid="B10-jpm-14-00863" ref-type="bibr">10</xref>]. Risk assessment at population level is thought to enable the identification and targeting of groups at elevated risk who stand to benefit the most from screening and may reduce or not offer screening for those who will benefit the least and for whom the benefit/risk ratio of screening is therefore worse [<xref rid="B7-jpm-14-00863" ref-type="bibr">7</xref>]. Personalized screening is potentially more cost-effective and may require less healthcare resources than current population-based approaches [<xref rid="B8-jpm-14-00863" ref-type="bibr">8</xref>,<xref rid="B9-jpm-14-00863" ref-type="bibr">9</xref>,<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>]. As it would increase the prevalence of true disease in the screened group, it could minimize the risk of overdiagnosis and unnecessary treatments [<xref rid="B5-jpm-14-00863" ref-type="bibr">5</xref>,<xref rid="B9-jpm-14-00863" ref-type="bibr">9</xref>,<xref rid="B12-jpm-14-00863" ref-type="bibr">12</xref>].</p><p>Many countries have well-established, organized, population-based screening programs in place for the early detection of breast [<xref rid="B13-jpm-14-00863" ref-type="bibr">13</xref>], cervical [<xref rid="B14-jpm-14-00863" ref-type="bibr">14</xref>], and colorectal cancers [<xref rid="B15-jpm-14-00863" ref-type="bibr">15</xref>]. Although melanoma is less common than other types of skin cancer, it is the most serious. While some European countries, such as Germany and France [<xref rid="B16-jpm-14-00863" ref-type="bibr">16</xref>,<xref rid="B17-jpm-14-00863" ref-type="bibr">17</xref>], have implemented national guidance on melanoma screening by physicians in a legal framework, these guidelines do not qualify as personalized screening due to a lack of risk assessment for screening eligibility and/or the absence of tailored screening frequencies based on individual risk [<xref rid="B18-jpm-14-00863" ref-type="bibr">18</xref>]. Consequently, there is a lack of evidence of effectiveness and cost-effectiveness in support of personalized melanoma screening [<xref rid="B19-jpm-14-00863" ref-type="bibr">19</xref>]. Early detection of melanoma, along with keratinocyte cancers such as basal cell carcinoma and squamous cell carcinoma, is therefore incidental and usually initiated by the patient or a health professional [<xref rid="B20-jpm-14-00863" ref-type="bibr">20</xref>]. The limitations of opportunistic early detection are reflected in inequitable melanoma outcomes among the community, with better outcomes for higher socioeconomic groups and those living near metropolitan centers [<xref rid="B21-jpm-14-00863" ref-type="bibr">21</xref>,<xref rid="B22-jpm-14-00863" ref-type="bibr">22</xref>,<xref rid="B23-jpm-14-00863" ref-type="bibr">23</xref>]. In Australia, treatment for melanoma and other keratinocyte cancers combined already confer the highest healthcare cost burden compared to other cancers [<xref rid="B24-jpm-14-00863" ref-type="bibr">24</xref>]. The burden from melanoma and other skin cancers is projected to increase substantially over the next two decades due to aging of the population, and increasing ultraviolet radiation exposure due to climate change [<xref rid="B25-jpm-14-00863" ref-type="bibr">25</xref>], which could further increase the risk of overdiagnosis and overtreatment [<xref rid="B26-jpm-14-00863" ref-type="bibr">26</xref>].</p><p>International recommendations [<xref rid="B19-jpm-14-00863" ref-type="bibr">19</xref>,<xref rid="B27-jpm-14-00863" ref-type="bibr">27</xref>] and Australian clinical practice guidelines already support personalized approaches to melanoma early detection, recommending clinicians identify people at high risk and conduct a skin examination, but there is limited evidence on how this should be implemented. A randomized, controlled trial of a personalized melanoma-screening program could help determine the benefits, costs, harms, and potential implementation strategy [<xref rid="B28-jpm-14-00863" ref-type="bibr">28</xref>,<xref rid="B29-jpm-14-00863" ref-type="bibr">29</xref>]. However, there are several complexities to establishing personalized screening programs that require decisions about the best approach to risk assessment, risk communication, risk thresholds, screening examination, and screening intervals.</p><p>To explore the feasibility and implementation strategies of personalized screening, we conducted a scoping review of relevant risk-based studies across various screen-detectable cancers. The World Health Organization&#8217;s principles and practice of screening for disease served as the foundational framework for this scoping review [<xref rid="B30-jpm-14-00863" ref-type="bibr">30</xref>]. By leveraging insights and lessons learned from research in other cancer types, there is a significant opportunity to inform the design of a potential future personalized melanoma-screening program.</p></sec><sec sec-type="methods" id="sec2-jpm-14-00863"><title>2. Methods</title><p>This review was conducted according to the PRISMA extension for scoping reviews and the Population/Concept/Context (PCC) Framework [<xref rid="B31-jpm-14-00863" ref-type="bibr">31</xref>] and registered on the Open Science Framework (registration DOI: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://doi.org/10.17605/OSF.IO/FC8W4">https://doi.org/10.17605/OSF.IO/FC8W4</uri>, accessed on 22 May 2024). The search process is displayed in <xref rid="jpm-14-00863-f001" ref-type="fig">Figure 1</xref>.</p><sec id="sec2dot1-jpm-14-00863"><title>2.1. Data Source</title><p>Electronic databases, including Medline, Embase, Cochrane central, PsychINFO, CINAHL, Scopus, ANZCTR, and clinicaltrials.gov, were systematically searched. Eligible articles for this scoping review included those published in English from January 2013 to May 2023.</p></sec><sec id="sec2dot2-jpm-14-00863"><title>2.2. Study Selection</title><p>English language reports published in peer-reviewed sources or listed on clinical trials databases were included, in accordance with specific inclusion and exclusion criteria. The search strategy, terms, and exclusion/inclusion criteria were developed in consultation with an experienced librarian at the University of Sydney. The detailed search strings for each database are provided in the <xref rid="app1-jpm-14-00863" ref-type="app">Supplementary Materials</xref>.</p><p>Studies were deemed eligible if they met all of the following criteria:<list list-type="bullet"><list-item><p>Participants from the adult general population;</p></list-item><list-item><p>Studies on personalized cancer-screening programs, where screening was tailored according to personal risk (beyond age or sex alone);</p></list-item><list-item><p>Focus on cancer(s);</p></list-item><list-item><p>January 2013 to May 2023, to focus on contemporary screening programs;</p></list-item><list-item><p>Research in humans.</p></list-item></list></p><p>The studies were excluded if they met any of the following criteria:<list list-type="bullet"><list-item><p>Written in a language other than English;</p></list-item><list-item><p>General screening (not risk-based) studies;</p></list-item><list-item><p>Reviews, letters, editorials;</p></list-item><list-item><p>Evaluations of hypothetical personalized cancer screening.</p></list-item></list></p></sec><sec id="sec2dot3-jpm-14-00863"><title>2.3. Data Extraction</title><p>Data extraction was performed independently by two reviewers, and discrepancies were addressed through discussion. Key variables from each paper were compiled in a data extraction framework and included the following: author, year, country, study design, primary aim, cancer type, study period, outcomes and measures, risk assessment, risk thresholds, screening intervals, participants characteristics, outcomes measured, and results.</p></sec><sec id="sec2dot4-jpm-14-00863"><title>2.4. Quality Assessment</title><p>Quality assessment was carried out using the Cochrane Risk of Bias Tool for Randomized Controlled Trials [<xref rid="B32-jpm-14-00863" ref-type="bibr">32</xref>] and the Risk Of Bias In Non-randomized Studies&#8212;of Interventions (ROBINS-I) [<xref rid="B33-jpm-14-00863" ref-type="bibr">33</xref>] for non-randomized studies.</p></sec></sec><sec sec-type="results" id="sec3-jpm-14-00863"><title>3. Results</title><p>A total of 2205 records were identified. Five additional papers were found through hand searching. After removing 919 duplicates, 1292 articles underwent title and abstract screening. Subsequently, 111 were selected for full-text review, with 49 being excluded (detailed reasons are provided in the <xref rid="app1-jpm-14-00863" ref-type="app">Supplementary Materials</xref>). Reasons for exclusion were no access to full text (<italic toggle="yes">n</italic> = 14), review (<italic toggle="yes">n</italic> = 2), wrong study design (<italic toggle="yes">n</italic> = 24), wrong participants (<italic toggle="yes">n</italic> = 5), and editorials/ letter/ comments/ opinion (<italic toggle="yes">n</italic> = 4) (<xref rid="jpm-14-00863-f001" ref-type="fig">Figure 1</xref>).</p><p>This broader search retrieved 62 articles. Of these, 42 studies were focused on modeling or health economics (<italic toggle="yes">n</italic> = 27), reported on screening sub-studies (<italic toggle="yes">n</italic> = 8), or were categorized as &#8216;other&#8217; (<italic toggle="yes">n</italic> = 7), and will be reported in a separate review. For this scoping review, 20 studies were selected, including 16 distinct personalized cancer-screening studies and 4 study protocols that focused on the evaluation of personalized cancer screening. Due to overlap with the identified results articles, the 4 protocol papers were excluded from this scoping review. Thus, the present review focuses on the 16 articles that reported evaluations of personalized cancer-screening implementation, including the key study components and outcomes (<xref rid="jpm-14-00863-f001" ref-type="fig">Figure 1</xref>). Overall, the studies included were of good quality. The overall risk of bias assessment for each study is provided in <xref rid="app1-jpm-14-00863" ref-type="app">Supplementary Materials</xref>.</p><sec id="sec3dot1-jpm-14-00863"><title>3.1. Key Characteristics of Eligible Studies</title><p>The key characteristics of the 16 studies are detailed in <xref rid="jpm-14-00863-t001" ref-type="table">Table 1</xref>. Most studies were published from 2020 onwards. The majority of study designs were randomized controlled trials (<italic toggle="yes">n</italic> = 8) [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>,<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>,<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>,<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>,<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>,<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>,<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>,<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>], followed by cohort studies (<italic toggle="yes">n</italic> = 2) [<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>,<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>]. Others included a non-randomized controlled trial [<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>], feasibility [<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>] and proof-of-concept [<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>], mixed-methods [<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>], pre&#8211;post implementation [<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>], and focus group [<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>] studies.</p></sec><sec id="sec3dot2-jpm-14-00863"><title>3.2. Cancer Types</title><p>The included studies mainly focused on breast cancer (<italic toggle="yes">n</italic> = 7) [<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>,<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>,<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>,<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>,<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>,<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>,<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>], colorectal cancer (<italic toggle="yes">n</italic> = 5) [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>,<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>,<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>,<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>,<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>], prostate cancer (<italic toggle="yes">n</italic> = 2) [<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>,<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>], lung cancer (<italic toggle="yes">n</italic> = 1) [<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>], and ovarian cancer (<italic toggle="yes">n</italic> = 1) [<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>].</p></sec><sec id="sec3dot3-jpm-14-00863"><title>3.3. Study Locations</title><p>The study locations included six in European countries [<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>,<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>,<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>,<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>,<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>,<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>], four in North America [<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>,<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>,<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>,<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>], three in Australia [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>,<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>,<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>], and three in Asian countries [<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>,<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>,<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>].</p></sec><sec sec-type="subjects" id="sec3dot4-jpm-14-00863"><title>3.4. Participants</title><p>The study sample sizes varied greatly, spanning from over 1 million participants [<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>] to as few as slightly over a hundred [<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>]. Furthermore, studies varied widely in eligibility criteria, risk assessment tools, risk thresholds, and other key elements. For example, the cancer-screening programs ranged widely in terms of the age ranges considered for participation. In the context of breast cancer, most studies targeted unaffected women between 40 and 70 years [<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>,<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>,<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>,<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>,<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>], while Gareth Evans et al. specifically concentrated on women who were approaching the age of 60 years [<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>]. For colorectal cancer screening, adults 25 to 75 years were included [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>,<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>,<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>,<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>,<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>]. Prostate cancer screening included males after reaching adulthood [<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>,<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>], while ovarian cancer screening recruited females once they turned 18 [<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>].</p></sec><sec id="sec3dot5-jpm-14-00863"><title>3.5. Risk Assessments</title><p>Tools used for risk assessment in each study are presented in <xref rid="jpm-14-00863-t002" ref-type="table">Table 2</xref>. Most studies used multiple data sources to predict an individual&#8217;s risk of developing cancer. Among the combinations with different approaches found in the 16 studies, eight incorporated self-reported questionnaires, blood, and/or saliva tests, and validated risk prediction model [<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>,<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>,<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>,<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>,<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>,<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>,<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>]. Three studies combined questionnaires with blood/saliva test results [<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>,<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>,<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>]. One study combined questionnaire data with polygenic risk score and a risk prediction model [<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>]. Five studies relied solely on self-reported questionnaire data for risk estimation [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>,<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>,<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>,<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>,<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>].</p></sec><sec id="sec3dot6-jpm-14-00863"><title>3.6. Risk Thresholds and Proposed Pathways</title><p>The risk thresholds and screening intervals are summarized for each cancer type in <xref rid="jpm-14-00863-t003" ref-type="table">Table 3</xref>. There was no consistency in the risk thresholds or number of groupings used in the included studies. The majority categorized potential screening participants into two (high and low) risk groups [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>,<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>,<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>,<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>,<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>,<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>,<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>,<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>] or three groups [<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>,<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>,<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>,<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>,<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>,<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>,<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>], while two studies incorporated four risk groups [<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>,<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>]. Several variations were also found with regard to the proposed screening intervals. Most screening intervals were based on a combination of participant&#8217;s age, family history, and risk level, resulting in a range of two to eight proposed screening pathways. Four studies did not propose pathway recommendations [<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>,<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>,<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>].</p><p>In a mixed-methods study from Brooks et al. [<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>], three risk categories were defined based on 10-year/remaining lifetime risk, namely less than 15% as average risk, 15&#8211;25% as higher than average, and 25% and above as high risk. The corresponding screening pathways were determined based on both participants age and their estimated risk levels. For those categorized as higher than average risk, apart from age and risk thresholds, screening pathways were also determined according to their residence location. For instance, participants in the Province of Ontario underwent an annual mammogram, while those residing in the Province of Qu&#233;bec followed a mammogram screening schedule of everyone to two years, with the possibility of incorporating ultrasound assessments if breast density exceeded 75%. In a separate study conducted in the United Kingdom [<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>], risk thresholds were classified based on 10-year risk, including low risk (&#8804;1.5%), average risk (1.5&#8211;4.99%), moderate risk (5&#8211;7.99%), and high risk (&#8805;8%). In contrast to the approach of Brooks et al. [<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>], the screening pathways in this study were solely dependent upon the assigned risk categories. For participants categorized as low to moderate risk, their screening frequency was every 3 years, while those in the high-risk group should follow an 18-month screening schedule. Detailed information specific to each study is available in <xref rid="jpm-14-00863-t003" ref-type="table">Table 3</xref>.</p></sec><sec id="sec3dot7-jpm-14-00863"><title>3.7. Key Components of Eligible Studies</title><p>The key components of the reviewed studies extracted include their primary outcomes, measurement methodologies, and main findings. Out of 16 studies, the majority directed their focus towards the practical consideration inherent in the newly proposed personalized screening approach. Two studies were not completed at the time of conducting this scoping review [<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>,<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>], and two papers only presented study protocols without any released results [<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>,<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>]. The primary outcomes in the selected studies are summarized in line with the World Health Organization (WHO) Wilson Framework (condition, test, treatment, and screening program) [<xref rid="B30-jpm-14-00863" ref-type="bibr">30</xref>] and displayed in <xref rid="jpm-14-00863-t004" ref-type="table">Table 4</xref>.</p><sec id="sec3dot7dot1-jpm-14-00863"><title>3.7.1. Screening Process and Evaluation</title><p>Four studies conducted an analysis of recruitment outcomes by assessing the acceptability and/or feasibility of the suggested screening approach [<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>,<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>,<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>,<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>]. Six studies evaluated screening by reporting the participation rate of the targeted population who underwent screening over subsequent follow-up examinations [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>,<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>,<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>,<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>,<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>,<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>]. Three studies reported the percentage of the screened population that required further assessment [<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>,<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>,<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>]. Another three studies focused on longer term outcome measurements, including morbidity [<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>] and mortality [<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>,<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>]. Two studies addressed other aspects within the screening process; one of them compared concordance between participants&#8217; preferences and ordered screening test [<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>], while the other explored the adoption of healthy behaviors following participation in a screening program [<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>].</p></sec><sec id="sec3dot7dot2-jpm-14-00863"><title>3.7.2. Main Outcomes of Screening</title><p>The primary outcomes of this scoping review include the potential benefits and harms associated with each screening program, categorized by cancer type and summarized in <xref rid="jpm-14-00863-t005" ref-type="table">Table 5</xref>. The majority of studies concluded that the evaluated screening strategies were feasible and cost-effective. Potential benefits included improved cancer knowledge [<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>], positive attitudes and screening examination uptake [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>,<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>,<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>,<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>,<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>,<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>,<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>,<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>], a higher cancer detection rate at an early stage [<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>], reduction in cancer-related deaths [<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>], and cost-effectiveness [<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>,<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>].</p><p>The most frequently identified harms were false positive screening results and overdiagnosis [<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>,<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>,<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>,<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>,<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>]. Other potential harms included higher costs [<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>,<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>] and failure to align with participants&#8217; preferences in a clinical setting [<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>].</p><p>Potential benefts and harms were unassessable for the studies still underway [<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>,<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>] or were presented in protocol format only [<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>,<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>].</p></sec><sec id="sec3dot7dot3-jpm-14-00863"><title>3.7.3. Results by Cancer Types</title><p>In the context of breast cancer, uptake of the personalized screening program was acceptable [<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>], with positive feedback received from the participants [<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>,<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>], and the proposed personalized screening approach resulted in an increased cancer detection rate among all groups [<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>].</p><p>For colorectal cancer, the implementation of the suggested personalized screening approaches resulted in a higher participation rate for all screening groups [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>,<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>] or high-risk groups only [<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>]. Chen et al. found that the proposed risk-based screening led to an increased cancer detection rate while requiring a reduced number of colonoscopies to be performed [<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>].</p><p>For the two prostate-cancer-screening studies, both studies observed an increased proportion of men adhering to the risk-appropriate recommended prostate-specific antigen (PSA) test schedules [<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>,<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>].</p><p>Regarding other cancer types, the use of a lung cancer risk prediction model was tested and found to be effective for identifying high-risk individuals who would be suitable for lung cancer screening [<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>], while a personalized ovarian cancer-screening program was appraised as acceptable and satisfactory by the participants, as indicated by validated questionnaires [<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>].</p></sec></sec></sec><sec sec-type="discussion" id="sec4-jpm-14-00863"><title>4. Discussion</title><p>There has been increasing interest in personalized cancer screening over the past decade, alongside accumulating evidence on its potential advantages compared to population-based cancer screening which may be unnecessary for those at low risk, and not intensive enough for those at high or very high risk. In this scoping review, we identified several key components and outcomes that may assist in the design and evaluation of future personalized screening studies and programs for implementation in melanoma settings. Clinical guidelines already recommend personalized approaches to early detection of melanoma, yet evidence on the benefits and harms of screening is currently insufficient. The targeted screening interventions reviewed 16 studies reported on personal risk-assessment design, tailored follow-up intervals for future check-ups, and primary outcomes of interest across multiple cancer types. While none specially targeted melanoma, these studies explored important aspects of the screening process that could be applicable to personalized melanoma screening. These findings are discussed within the framework of the WHO screening guidelines.</p><p>Prior investigations into cancer screening across various cancer types have been included into this review. While population-based screening programs for ovarian cancer have not been approved globally, this scoping review included the feasibility study for this cancer type, given the ongoing efforts in this area [<xref rid="B49-jpm-14-00863" ref-type="bibr">49</xref>]. The screening studies included in this review demonstrated participation rates of over 50%, which were deemed acceptable [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>,<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>,<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>,<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>,<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>,<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>]. The WHO guidelines highlight the importance of participant engagement to maximize recruitment to screening, as high participation rates form the foundation for effective screening programs. Several of the reviewed studies examined whether personalized approaches improved the acceptability and/or feasibility of cancer screening [<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>,<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>,<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>,<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>]. These studies showed positive attitudes towards the personalized cancer screening programs implemented, which further indicates that personalized screening programs may engage those that benefit the most from screening more effectively. Although none of the included studies specifically addressed melanoma screening, it is worthwhile to examine shared characteristics in the design of personalized screening programs, such as personalized cut-off scores for different demographic cohorts, proposed screening pathways, and suggested follow-up intervals. Such analysis would further enrich the groundwork for designing future melanoma screening pilot studies. We found that various risk assessment strategies were incorporated in the design of the personalized screening programs to enable more accurate risk assessment. The commonly self-reported risk factors included in the risk tools were age, gender, race, personal cancer history, family history of cancer, and lifestyle factors, which were also relevant for defining melanoma high-risk individuals. Moreover, some studies also included the assessment of genetic- or biomarkers from blood or saliva samples. Currently, in the context of melanoma, several self-reported risk factor online tools are already freely accessible to both health professionals and the public [<xref rid="B50-jpm-14-00863" ref-type="bibr">50</xref>,<xref rid="B51-jpm-14-00863" ref-type="bibr">51</xref>], which calculate personal melanoma risk based on general risk factors plus melanoma specific ones such as phenotypic characteristics (hair, skin, eye color), sun or sunbed exposure, and melanocytic nevus (moles) counts. Scientific literature has highlighted concerns regarding the lack of validation in current melanoma risk prediction models [<xref rid="B52-jpm-14-00863" ref-type="bibr">52</xref>,<xref rid="B53-jpm-14-00863" ref-type="bibr">53</xref>]. This issue must be addressed when designing personalized screening strategies, as a validated risk-prediction model is essential for ensuring effective and valid personalized melanoma screening. Genomic risk factors, such as polygenic scores, are also related to risk of many cancers, including melanoma, and are anticipated to be incorporated into risk prediction tools more commonly [<xref rid="B54-jpm-14-00863" ref-type="bibr">54</xref>,<xref rid="B55-jpm-14-00863" ref-type="bibr">55</xref>]. In addition, our search showed that ten studies included polygenic scores in their risk assessment process, suggesting a necessity to further explore whether the addition of genomic information improves risk assessment enough to be incorporated in personalized screening programs, as this is more complex and costly compared to self-reported risk only.</p><p>Two studies in this review reported an increased cancer detection rate [<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>,<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>]. While this can be seen as a benefit, it could also be a result of length&#8211;time bias and also raises concerns about potential overdiagnosis and overtreatment [<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>,<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>,<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>,<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>,<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>]. Despite the demonstrated benefits of nationwide mammographic screening programs in reducing breast cancer deaths reported in many countries [<xref rid="B56-jpm-14-00863" ref-type="bibr">56</xref>,<xref rid="B57-jpm-14-00863" ref-type="bibr">57</xref>,<xref rid="B58-jpm-14-00863" ref-type="bibr">58</xref>,<xref rid="B59-jpm-14-00863" ref-type="bibr">59</xref>,<xref rid="B60-jpm-14-00863" ref-type="bibr">60</xref>,<xref rid="B61-jpm-14-00863" ref-type="bibr">61</xref>], the overall effectiveness of screening is still debated due to evidence of potentially unnecessary treatments. Overdiagnosis is a major concern for melanoma screening, as incidence rates increased substantially over the past decade without concomitant decreases in mortality [<xref rid="B62-jpm-14-00863" ref-type="bibr">62</xref>]. In Australia, 54% of all melanomas (including melanoma in situ) and 15% of invasive melanomas are estimated to be over-diagnosed [<xref rid="B26-jpm-14-00863" ref-type="bibr">26</xref>] in the absence of a formal dedicated screening program [<xref rid="B63-jpm-14-00863" ref-type="bibr">63</xref>].</p><p>The ultimate goal of cancer-screening programs is to reduce mortality and morbidity [<xref rid="B29-jpm-14-00863" ref-type="bibr">29</xref>]. In the context of melanoma, no randomized controlled trial has evaluated the screening impact on melanoma mortality, although observational studies have suggested that having a screening examination during the past 3 years reduces the thickness of melanoma [<xref rid="B19-jpm-14-00863" ref-type="bibr">19</xref>,<xref rid="B22-jpm-14-00863" ref-type="bibr">22</xref>]. Based on the reviewed personalized screening programs in other cancers, morbidity and melanoma thickness might be a suitable primary parameter, given the low overall mortality risk from melanoma, particularly with advancements in targeted and immunotherapy treatments [<xref rid="B64-jpm-14-00863" ref-type="bibr">64</xref>,<xref rid="B65-jpm-14-00863" ref-type="bibr">65</xref>]. In addition, other considerations for implementing a personalized melanoma screening program in Australia should include medical intervention practices, healthcare accessibility across different regions, costs, and individual quality of life. Potential parameters in this context include the need for adjuvant or neoadjuvant treatment, individual&#8217;s quality of life, healthcare expenditure, or equitable access or outcomes. Given the variability in melanoma risk among individuals, influenced by factors such as age, gender, race, personal cancer history, family history of skin cancer, lifestyle factors, and phenotypic characteristics, the frequency of evaluations should be tailored to individual risk levels.</p><sec><title>Strengths and Limitations</title><p>Evidence collected from this scoping review encompassed multiple cancer types, research methods, study locations, and provided up-to-date evidence. In addition, this review summarized a wide variety of outcomes assessed, ranging from knowledge and attitudes to mortality. Given our particular interest in melanoma screening, it was a limitation that no studies associated with melanoma or skin cancer were discovered in the search; however, insights for melanoma screening can be gained from personalized screening studies and programs for other cancer types. Indeed, numerous parallels existed in the design of cancer-screening initiatives, including the essential elements considered for high-risk groups, primary outcomes of interest, and strategies for participants recruitment. Second, because of the nature of a scoping review, we included studies with diverse methodologies, populations, and primary outcomes. This heterogeneity can make it challenging to identify patterns across different studies. Furthermore, the search was restricted to English peer-reviewed articles, which potentially prevented us from exploring non-English datasets or screening programs in regions where English is not the official language.</p></sec></sec><sec sec-type="conclusions" id="sec5-jpm-14-00863"><title>5. Conclusions</title><p>Given the limited evidence available on personalized melanoma screening, this scoping review summarizes the key components and outcomes that personalized screening studies have considered across different cancer types over the past decade. In addition to traditional screening outcomes such as cancer mortality and incidence, acceptability and feasibility to recruit were also identified as important aspects to ensure optimal screening-program effectiveness. In addition, measurement of potential harms such as overdiagnosis and overtreatment, and the balance of benefits and harms across different risk groups, are essential considerations for any screening program going forward, particularly in the context of melanoma. The sensitivity, specificity, and positive predictive value of the proposed screening method are vital factors to ensure the program&#8217;s effectiveness in reducing melanoma-related morbidity and mortality. Insights from this review can assist researchers, clinicians, and policymakers in designing new studies and programs for personalized melanoma screening.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors express special thanks to Linda Finch for her contribution to the screening process, including title/abstract review, full text evaluation, and data extraction. Additionally, the authors acknowledge the invaluable assistance and support provided by all reviewers.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-jpm-14-00863"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/jpm14080863/s1">https://www.mdpi.com/article/10.3390/jpm14080863/s1</uri>, Table S1: Search Terms per Database; Table S2: Quality Assessment; Table S3: Reasons for Exclusion.</p><supplementary-material id="jpm-14-00863-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jpm-14-00863-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>L.Z.: Data curation, formal analysis, writing&#8212;original draft, writing&#8212;review and editing, visualization. A.K.S.: conceptualization, methodology, software, investigation, data curation, formal analysis, writing&#8212;review and editing. A.E.C.: conceptualization, methodology, investigation, resources, writing&#8212;review and editing, supervision, funding acquisition. M.J.: conceptualization, methodology, investigation, resources, investigation, data curation, formal analysis, writing&#8212;review and editing, visualization, supervision, project administration, funding acquisition. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable for scoping review.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data that support the study findings are accessible from the corresponding author upon request.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>All authors declare that they have no known competing interest that could have appeared to influence the work reported in this manuscript.</p></notes><ref-list><title>References</title><ref id="B1-jpm-14-00863"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bsc</surname><given-names>M.F.B.</given-names></name><name name-style="western"><surname>Me</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>M.I.</given-names></name><etal/></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="B2-jpm-14-00863"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name></person-group><article-title>Cancer statistics, 2022</article-title><source>CA Cancer J. Clin.</source><year>2022</year><volume>72</volume><fpage>7</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.3322/caac.21708</pub-id><pub-id pub-id-type="pmid">35020204</pub-id></element-citation></ref><ref id="B3-jpm-14-00863"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Learoyd</surname><given-names>D.L.</given-names></name></person-group><article-title>Estimating the magnitude of cancer overdiagnosis in Australia</article-title><source>Med. J. Aust.</source><year>2020</year><volume>213</volume><fpage>189</fpage><pub-id pub-id-type="doi">10.5694/mja2.50575</pub-id><pub-id pub-id-type="pmid">32277479</pub-id></element-citation></ref><ref id="B4-jpm-14-00863"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lew</surname><given-names>J.-B.</given-names></name><name name-style="western"><surname>Feletto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wade</surname><given-names>S.</given-names></name><name name-style="western"><surname>Caruana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>Nickson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Simms</surname><given-names>K.</given-names></name><name name-style="western"><surname>Procopio</surname><given-names>P.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>N.</given-names></name><name name-style="western"><surname>Worthington</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Benefits, harms and cost-effectiveness of cancer screening in Australia: An overview of modelling estimates</article-title><source>Public Health Res. Pract.</source><year>2019</year><volume>29</volume><fpage>29121913</fpage><pub-id pub-id-type="doi">10.17061/phrp2921913</pub-id><pub-id pub-id-type="pmid">31384886</pub-id></element-citation></ref><ref id="B5-jpm-14-00863"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marcus</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Prorok</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>DeVoto</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>B.S.</given-names></name></person-group><article-title>Conceptualizing overdiagnosis in cancer screening</article-title><source>JNCI J. Natl. Cancer Inst.</source><year>2015</year><volume>107</volume><fpage>djv014</fpage><pub-id pub-id-type="doi">10.1093/jnci/djv014</pub-id><pub-id pub-id-type="pmid">25663695</pub-id><pub-id pub-id-type="pmcid">PMC4334818</pub-id></element-citation></ref><ref id="B6-jpm-14-00863"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Hutchinson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Law</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>V.</given-names></name><name name-style="western"><surname>Usher-Smith</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Dennison</surname><given-names>R.A.</given-names></name></person-group><article-title>Acceptability of risk stratification within population-based cancer screening from the perspective of the general public: A mixed-methods systematic review</article-title><source>Health Expect.</source><year>2023</year><volume>26</volume><fpage>989</fpage><lpage>1008</lpage><pub-id pub-id-type="doi">10.1111/hex.13739</pub-id><pub-id pub-id-type="pmid">36852880</pub-id><pub-id pub-id-type="pmcid">PMC10154794</pub-id></element-citation></ref><ref id="B7-jpm-14-00863"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Law</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hutchinson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dennison</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Usher-Smith</surname><given-names>J.A.</given-names></name></person-group><article-title>Acceptability of risk stratification within population-based cancer screening from the perspective of healthcare professionals: A mixed methods systematic review and recommendations to support implementation</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0279201</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0279201</pub-id><pub-id pub-id-type="pmid">36827432</pub-id><pub-id pub-id-type="pmcid">PMC9956883</pub-id></element-citation></ref><ref id="B8-jpm-14-00863"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clift</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Dodwell</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>S.</given-names></name><name name-style="western"><surname>Petrou</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brady</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Hippisley-Cox</surname><given-names>J.</given-names></name></person-group><article-title>The current status of risk-stratified breast screening</article-title><source>Br. J. Cancer</source><year>2022</year><volume>126</volume><fpage>533</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/s41416-021-01550-3</pub-id><pub-id pub-id-type="pmid">34703006</pub-id><pub-id pub-id-type="pmcid">PMC8854575</pub-id></element-citation></ref><ref id="B9-jpm-14-00863"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hull</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Rees</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>L.</given-names></name><name name-style="western"><surname>Koo</surname><given-names>S.</given-names></name></person-group><article-title>A risk-stratified approach to colorectal cancer prevention and diagnosis</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><year>2020</year><volume>17</volume><fpage>773</fpage><lpage>780</lpage><pub-id pub-id-type="doi">10.1038/s41575-020-00368-3</pub-id><pub-id pub-id-type="pmid">33067592</pub-id><pub-id pub-id-type="pmcid">PMC7562765</pub-id></element-citation></ref><ref id="B10-jpm-14-00863"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>National Lung Screening Trial Research Team</collab><name name-style="western"><surname>Aberle</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Black</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Clapp</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Fagerstrom</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Gareen</surname><given-names>I.F.</given-names></name><name name-style="western"><surname>Gatsonis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Marcus</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>Reduced lung-cancer mortality with low-dose computed tomographic screening</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>365</volume><fpage>395</fpage><lpage>409</lpage><pub-id pub-id-type="doi">10.1056/nejmoa1102873</pub-id><pub-id pub-id-type="pmid">21714641</pub-id><pub-id pub-id-type="pmcid">PMC4356534</pub-id></element-citation></ref><ref id="B11-jpm-14-00863"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emery</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>A Jenkins</surname><given-names>M.</given-names></name><name name-style="western"><surname>Saya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chondros</surname><given-names>P.</given-names></name><name name-style="western"><surname>Oberoi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Milton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Novy</surname><given-names>K.</given-names></name><name name-style="western"><surname>Habgood</surname><given-names>E.</given-names></name><name name-style="western"><surname>Karnchanachari</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pirotta</surname><given-names>M.</given-names></name><etal/></person-group><article-title>The Colorectal cancer RISk Prediction (CRISP) trial: A randomised controlled trial of a decision support tool for risk-stratified colorectal cancer screening</article-title><source>Br. J. Gen. Pract.</source><year>2023</year><volume>73</volume><fpage>e556</fpage><lpage>e565</lpage><pub-id pub-id-type="doi">10.3399/BJGP.2022.0480</pub-id><pub-id pub-id-type="pmid">37012077</pub-id><pub-id pub-id-type="pmcid">PMC10098832</pub-id></element-citation></ref><ref id="B12-jpm-14-00863"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lansdorp-Vogelaar</surname><given-names>I.</given-names></name><name name-style="western"><surname>Meester</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Jonge</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buron</surname><given-names>A.</given-names></name><name name-style="western"><surname>Haug</surname><given-names>U.</given-names></name><name name-style="western"><surname>Senore</surname><given-names>C.</given-names></name></person-group><article-title>Risk-stratified strategies in population screening for colorectal cancer</article-title><source>Int. J. Cancer</source><year>2022</year><volume>150</volume><fpage>397</fpage><lpage>405</lpage><pub-id pub-id-type="doi">10.1002/ijc.33784</pub-id><pub-id pub-id-type="pmid">34460107</pub-id><pub-id pub-id-type="pmcid">PMC9293115</pub-id></element-citation></ref><ref id="B13-jpm-14-00863"><label>13.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>Existence of National Screening Program for Breast Cancer</article-title><year>2022</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/data/gho/data/indicators/indicator-details/GHO/existence-of-national-screening-program-for-breast-cancer" ext-link-type="uri">https://www.who.int/data/gho/data/indicators/indicator-details/GHO/existence-of-national-screening-program-for-breast-cancer</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-04-23">(accessed on 23 April 2024)</date-in-citation></element-citation></ref><ref id="B14-jpm-14-00863"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruni</surname><given-names>L.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>B.</given-names></name><name name-style="western"><surname>Roura</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alemany</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cowan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herrero</surname><given-names>R.</given-names></name><name name-style="western"><surname>Poljak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Murillo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Broutet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Riley</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>Cervical cancer screening programmes and age-specific coverage estimates for 202 countries and territories worldwide: A review and synthetic analysis</article-title><source>Lancet Glob. Health</source><year>2022</year><volume>10</volume><fpage>e1115</fpage><lpage>e1127</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(22)00241-8</pub-id><pub-id pub-id-type="pmid">35839811</pub-id><pub-id pub-id-type="pmcid">PMC9296658</pub-id></element-citation></ref><ref id="B15-jpm-14-00863"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schreuders</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Ruco</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rabeneck</surname><given-names>L.</given-names></name><name name-style="western"><surname>E Schoen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>J.J.Y.</given-names></name><name name-style="western"><surname>Young</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Kuipers</surname><given-names>E.J.</given-names></name></person-group><article-title>Colorectal cancer screening: A global overview of existing programmes</article-title><source>Gut</source><year>2015</year><volume>64</volume><fpage>1637</fpage><lpage>1649</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2014-309086</pub-id><pub-id pub-id-type="pmid">26041752</pub-id></element-citation></ref><ref id="B16-jpm-14-00863"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breitbart</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Waldmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nolte</surname><given-names>S.</given-names></name><name name-style="western"><surname>Capellaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Greinert</surname><given-names>R.</given-names></name><name name-style="western"><surname>Volkmer</surname><given-names>B.</given-names></name><name name-style="western"><surname>Katalinic</surname><given-names>A.</given-names></name></person-group><article-title>Systematic skin cancer screening in Northern Germany</article-title><source>J. Am. Acad. Dermatol.</source><year>2012</year><volume>66</volume><fpage>201</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2010.11.016</pub-id><pub-id pub-id-type="pmid">22074699</pub-id></element-citation></ref><ref id="B17-jpm-14-00863"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rat</surname><given-names>C.</given-names></name><name name-style="western"><surname>Blachier</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hild</surname><given-names>S.</given-names></name><name name-style="western"><surname>Molinie</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gaultier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dreno</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>J.-M.</given-names></name></person-group><article-title>Targeted screening for melanoma after a 5-year follow-up: Comparison of melanoma incidence and lesion thickness at diagnosis in screened (versus unscreened) patients</article-title><source>La Presse M&#233;dicale Open</source><year>2021</year><volume>2</volume><fpage>100013</fpage><pub-id pub-id-type="doi">10.1016/j.lpmope.2021.100013</pub-id></element-citation></ref><ref id="B18-jpm-14-00863"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunlop</surname><given-names>K.L.A.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Zahed</surname><given-names>H.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rankin</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Cust</surname><given-names>A.E.</given-names></name></person-group><article-title>Implementation considerations for risk-tailored cancer screening in the population: A scoping review</article-title><source>Prev. Med.</source><year>2024</year><volume>181</volume><fpage>107897</fpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2024.107897</pub-id><pub-id pub-id-type="pmid">38378124</pub-id><pub-id pub-id-type="pmcid">PMC11106520</pub-id></element-citation></ref><ref id="B19-jpm-14-00863"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Henrikson</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Ivlev</surname><given-names>I.</given-names></name><name name-style="western"><surname>Blasi</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Senger</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Perdue</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>J.S.</given-names></name></person-group><article-title>Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force</article-title><source>JAMA</source><year>2023</year><volume>329</volume><fpage>1296</fpage><lpage>1307</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.3262</pub-id><pub-id pub-id-type="pmid">37071090</pub-id></element-citation></ref><ref id="B20-jpm-14-00863"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhave</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.</given-names></name><name name-style="western"><surname>McInerney-Leo</surname><given-names>A.</given-names></name><name name-style="western"><surname>E Cust</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lawn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Janda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mar</surname><given-names>V.J.</given-names></name></person-group><article-title>Management of cutaneous melanoma in Australia: A narrative review</article-title><source>Med. J. Aust.</source><year>2023</year><volume>218</volume><fpage>426</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.5694/mja2.51910</pub-id><pub-id pub-id-type="pmid">37120760</pub-id></element-citation></ref><ref id="B21-jpm-14-00863"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reyes-Marcelino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tabbakh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Espinoza</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sinclair</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Y.-J.</given-names></name><name name-style="western"><surname>McLoughlin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Caruana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Pe&#241;as</surname><given-names>P.</given-names></name><name name-style="western"><surname>Guitera</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>J.F.</given-names></name><etal/></person-group><article-title>Prevalence of skin examination behaviours among Australians over time</article-title><source>Cancer Epidemiol.</source><year>2021</year><volume>70</volume><fpage>101874</fpage><pub-id pub-id-type="doi">10.1016/j.canep.2020.101874</pub-id><pub-id pub-id-type="pmid">33341599</pub-id></element-citation></ref><ref id="B22-jpm-14-00863"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aitken</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Elwood</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baade</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Youl</surname><given-names>P.</given-names></name><name name-style="western"><surname>English</surname><given-names>D.</given-names></name></person-group><article-title>Clinical whole-body skin examination reduces the incidence of thick melanomas</article-title><source>Int. J. Cancer</source><year>2010</year><volume>126</volume><fpage>450</fpage><lpage>458</lpage><pub-id pub-id-type="doi">10.1002/ijc.24747</pub-id><pub-id pub-id-type="pmid">19609948</pub-id></element-citation></ref><ref id="B23-jpm-14-00863"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geller</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Elwood</surname><given-names>M.</given-names></name><name name-style="western"><surname>Swetter</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>J.</given-names></name><name name-style="western"><surname>Youl</surname><given-names>P.H.</given-names></name><name name-style="western"><surname>Demierre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baade</surname><given-names>P.D.</given-names></name></person-group><article-title>Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia</article-title><source>Cancer</source><year>2009</year><volume>115</volume><fpage>1318</fpage><lpage>1327</lpage><pub-id pub-id-type="doi">10.1002/cncr.24162</pub-id><pub-id pub-id-type="pmid">19189368</pub-id></element-citation></ref><ref id="B24-jpm-14-00863"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>L.G.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>S.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goldsbury</surname><given-names>D.</given-names></name><name name-style="western"><surname>Green</surname><given-names>A.C.</given-names></name></person-group><article-title>The economics of skin cancer prevention with implications for Australia and New Zealand: Where are we now?</article-title><source>Public Health Res. Pract.</source><year>2022</year><volume>32</volume><fpage>31502119</fpage><pub-id pub-id-type="doi">10.17061/phrp31502119</pub-id><pub-id pub-id-type="pmid">35290994</pub-id></element-citation></ref><ref id="B25-jpm-14-00863"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>Q.</given-names></name><name name-style="western"><surname>O&#8217;connell</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Kahn</surname><given-names>C.</given-names></name><name name-style="western"><surname>Caruana</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pesola</surname><given-names>F.</given-names></name><name name-style="western"><surname>Sasieni</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grogan</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Aranda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cabasag</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Cancer incidence and mortality in Australia from 2020 to 2044 and an exploratory analysis of the potential effect of treatment delays during the COVID-19 pandemic: A statistical modelling study</article-title><source>Lancet Public Health</source><year>2022</year><volume>7</volume><fpage>e537</fpage><lpage>e548</lpage><pub-id pub-id-type="doi">10.1016/S2468-2667(22)00090-1</pub-id><pub-id pub-id-type="pmid">35660215</pub-id><pub-id pub-id-type="pmcid">PMC9159737</pub-id></element-citation></ref><ref id="B26-jpm-14-00863"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muzumdar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>P.</given-names></name><name name-style="western"><surname>Grant-Kels</surname><given-names>J.M.</given-names></name></person-group><article-title>Evidence concerning the accusation that melanoma is overdiagnosed</article-title><source>J. Am. Acad. Dermatol.</source><year>2021</year><volume>85</volume><fpage>841</fpage><lpage>846</lpage><pub-id pub-id-type="doi">10.1016/j.jaad.2021.06.010</pub-id><pub-id pub-id-type="pmid">34116095</pub-id></element-citation></ref><ref id="B27-jpm-14-00863"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watts</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dieng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Menzies</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cust</surname><given-names>A.</given-names></name></person-group><article-title>Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: A systematic review</article-title><source>Br. J. Dermatol.</source><year>2015</year><volume>172</volume><fpage>33</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1111/bjd.13403</pub-id><pub-id pub-id-type="pmid">25204572</pub-id></element-citation></ref><ref id="B28-jpm-14-00863"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexeyev</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Dekio</surname><given-names>I.</given-names></name><name name-style="western"><surname>Layton</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>H.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zouboulis</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Patrick</surname><given-names>S.</given-names></name></person-group><article-title>Why we continue to use the name <italic toggle="yes">Propionibacterium acnes</italic></article-title><source>Br. J. Dermatol.</source><year>2018</year><volume>179</volume><fpage>1227</fpage><pub-id pub-id-type="doi">10.1111/bjd.17085</pub-id><pub-id pub-id-type="pmid">30101491</pub-id></element-citation></ref><ref id="B29-jpm-14-00863"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cust</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Neale</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Baade</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Green</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Khosrotehrani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mar</surname><given-names>V.</given-names></name><name name-style="western"><surname>Soyer</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Whiteman</surname><given-names>D.C.</given-names></name></person-group><article-title>Early detection of melanoma: A consensus report from the Australian Skin and Skin Cancer Research Centre Melanoma Screening Summit</article-title><source>Aust. N. Z. J. Public Health</source><year>2020</year><volume>44</volume><fpage>111</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1111/1753-6405.12972</pub-id><pub-id pub-id-type="pmid">32190955</pub-id></element-citation></ref><ref id="B30-jpm-14-00863"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Wilson</surname><given-names>J.M.G.</given-names></name><name name-style="western"><surname>Jungner</surname><given-names>G.</given-names></name><collab>World Health Organization</collab></person-group><source>Principles and Practice of Screening for Disease</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>1968</year></element-citation></ref><ref id="B31-jpm-14-00863"><label>31.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Joanna Briggs Institute</collab></person-group><article-title>Scoping Reviews</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://guides.library.unisa.edu.au/ScopingReviews" ext-link-type="uri">https://guides.library.unisa.edu.au/ScopingReviews</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-05-23">(accessed on 23 May 2023)</date-in-citation></element-citation></ref><ref id="B32-jpm-14-00863"><label>32.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Cochrane Methods</collab></person-group><article-title>Risk of Bias 2 (RoB 2) Tool</article-title><year>2021</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://methods.cochrane.org/risk-bias-2" ext-link-type="uri">https://methods.cochrane.org/risk-bias-2</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-05-23">(accessed on 23 May 2023)</date-in-citation></element-citation></ref><ref id="B33-jpm-14-00863"><label>33.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Cochrane Methods</collab></person-group><article-title>ROBINS-I Tool</article-title><year>2017</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://methods.cochrane.org/robins-I" ext-link-type="uri">https://methods.cochrane.org/robins-I</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-05-23">(accessed on 23 May 2023)</date-in-citation></element-citation></ref><ref id="B34-jpm-14-00863"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Comparison of Colonoscopy, Fecal Immunochemical Test, and Risk-Adapted Approach in a Colorectal Cancer Screening Trial (TARGET-C)</article-title><source>Clin. Gastroenterol. Hepatol.</source><year>2023</year><volume>21</volume><fpage>808</fpage><lpage>818</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2022.08.003</pub-id><pub-id pub-id-type="pmid">35964896</pub-id></element-citation></ref><ref id="B35-jpm-14-00863"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schroy</surname><given-names>P.C.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Duhovic</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Heeren</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>W.</given-names></name><name name-style="western"><surname>Apodaca</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.B.</given-names></name></person-group><article-title>Risk Stratification and Shared Decision Making for Colorectal Cancer Screening: A Randomized Controlled Trial</article-title><source>Med. Decis. Mak.</source><year>2016</year><volume>36</volume><fpage>526</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1177/0272989X15625622</pub-id><pub-id pub-id-type="pmcid">PMC4818180</pub-id><pub-id pub-id-type="pmid">26785715</pub-id></element-citation></ref><ref id="B36-jpm-14-00863"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freds&#248;e</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koetsenruyter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vedsted</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kirkegaard</surname><given-names>P.</given-names></name><name name-style="western"><surname>V&#230;th</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>A.</given-names></name><name name-style="western"><surname>&#216;rntoft</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>S&#248;rensen</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Bro</surname><given-names>F.</given-names></name></person-group><article-title>The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial</article-title><source>PLoS Med.</source><year>2020</year><volume>17</volume><elocation-id>e1003033</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pmed.1003033</pub-id><pub-id pub-id-type="pmid">32032355</pub-id><pub-id pub-id-type="pmcid">PMC7006905</pub-id></element-citation></ref><ref id="B37-jpm-14-00863"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Field</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Whynes</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Devaraj</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brain</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Eisen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gosney</surname><given-names>J.</given-names></name><name name-style="western"><surname>A Green</surname><given-names>B.</given-names></name><name name-style="western"><surname>A Holemans</surname><given-names>J.</given-names></name><etal/></person-group><article-title>UK Lung Cancer RCT Pilot Screening Trial: Baseline findings from the screening arm provide evidence for the potential implementation of lung cancer screening</article-title><source>Thorax</source><year>2016</year><volume>71</volume><fpage>161</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1136/thoraxjnl-2015-207140</pub-id><pub-id pub-id-type="pmid">26645413</pub-id><pub-id pub-id-type="pmcid">PMC4752629</pub-id></element-citation></ref><ref id="B38-jpm-14-00863"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Esserman</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Study</surname><given-names>W.</given-names></name><name name-style="western"><surname>Athena</surname><given-names>I.</given-names></name></person-group><article-title>The WISDOM Study: Breaking the deadlock in the breast cancer screening debate</article-title><source>NPJ Breast Cancer</source><year>2017</year><volume>3</volume><fpage>34</fpage><pub-id pub-id-type="doi">10.1038/s41523-017-0035-5</pub-id><pub-id pub-id-type="pmid">28944288</pub-id><pub-id pub-id-type="pmcid">PMC5597574</pub-id></element-citation></ref><ref id="B39-jpm-14-00863"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trevena</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Meiser</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dobbins</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mazza</surname><given-names>D.</given-names></name><name name-style="western"><surname>Emery</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>J.</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barlow-Stewart</surname><given-names>K.</given-names></name><name name-style="western"><surname>Naicker</surname><given-names>S.</given-names></name></person-group><article-title>Which Test Is Best? A Cluster-Randomized Controlled Trial of a Risk Calculator and Recommendations on Colorectal Cancer Screening Behaviour in General Practice</article-title><source>Public Health Genom.</source><year>2022</year><volume>25</volume><fpage>193</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1159/000526628</pub-id><pub-id pub-id-type="pmid">36195055</pub-id></element-citation></ref><ref id="B40-jpm-14-00863"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saya</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chondros</surname><given-names>P.</given-names></name><name name-style="western"><surname>McNamara</surname><given-names>M.</given-names></name><name name-style="western"><surname>King</surname><given-names>M.</given-names></name><name name-style="western"><surname>Milton</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lourenco</surname><given-names>R.D.A.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fishman</surname><given-names>G.</given-names></name><name name-style="western"><surname>Marker</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The SCRIPT trial: Study protocol for a randomised controlled trial of a polygenic risk score to tailor colorectal cancer screening in primary care</article-title><source>Trials</source><year>2022</year><volume>23</volume><fpage>810</fpage><pub-id pub-id-type="doi">10.1186/s13063-022-06734-7</pub-id><pub-id pub-id-type="pmid">36163034</pub-id><pub-id pub-id-type="pmcid">PMC9513012</pub-id></element-citation></ref><ref id="B41-jpm-14-00863"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>T.H.L.</given-names></name><name name-style="western"><surname>Yeoh</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Chew</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Riza</surname><given-names>N.K.M.</given-names></name><name name-style="western"><surname>Khng</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>S.-A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H.B.</given-names></name><etal/></person-group><article-title>BREAst screening Tailored for HEr (BREATHE)&#8212;A study protocol on personalised risk-based breast cancer screening programme</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0265965</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0265965</pub-id><pub-id pub-id-type="pmid">35358246</pub-id><pub-id pub-id-type="pmcid">PMC8970365</pub-id></element-citation></ref><ref id="B42-jpm-14-00863"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yen</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Tsau</surname><given-names>H.-S.</given-names></name><name name-style="western"><surname>Fann</surname><given-names>J.C.-Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.L.-S.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>S.Y.-H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.-C.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>S.-L.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>H.-M.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>W.-H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K.-J.</given-names></name><etal/></person-group><article-title>Population-Based Breast Cancer Screening with Risk-Based and Universal Mammography Screening Compared with Clinical Breast Examination: A Propensity Score Analysis of 1 429 890 Taiwanese Women</article-title><source>JAMA Oncol.</source><year>2016</year><volume>2</volume><fpage>915</fpage><lpage>921</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.0447</pub-id><pub-id pub-id-type="pmid">27030951</pub-id></element-citation></ref><ref id="B43-jpm-14-00863"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Evans</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>McWilliams</surname><given-names>L.</given-names></name><name name-style="western"><surname>Astley</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brentnall</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Cuzick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dobrashian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Duffy</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Gorman</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Harkness</surname><given-names>E.F.</given-names></name><name name-style="western"><surname>Harrison</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Quantifying the effects of risk-stratified breast cancer screening when delivered in real time as routine practice versus usual screening: The BC-Predict non-randomised controlled study (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04359420">NCT04359420</ext-link>)</article-title><source>Br. J. Cancer</source><year>2023</year><volume>128</volume><fpage>2063</fpage><lpage>2071</lpage><pub-id pub-id-type="doi">10.1038/s41416-023-02250-w</pub-id><pub-id pub-id-type="pmid">37005486</pub-id><pub-id pub-id-type="pmcid">PMC10066938</pub-id></element-citation></ref><ref id="B44-jpm-14-00863"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaba</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blyuss</surname><given-names>O.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lahoti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chandrasekaran</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kurzer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kalsi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sanderson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lanceley</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention</article-title><source>Cancers</source><year>2020</year><volume>12</volume><elocation-id>1241</elocation-id><pub-id pub-id-type="doi">10.3390/cancers12051241</pub-id><pub-id pub-id-type="pmid">32429029</pub-id><pub-id pub-id-type="pmcid">PMC7281662</pub-id></element-citation></ref><ref id="B45-jpm-14-00863"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laza-V&#225;squez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mart&#237;nez-Alonso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Forn&#233;-Izquierdo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vilaplana-Mayoral</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cruz-Esteve</surname><given-names>I.</given-names></name><name name-style="western"><surname>S&#225;nchez-L&#243;pez</surname><given-names>I.</given-names></name><name name-style="western"><surname>Re&#241;&#233;-Re&#241;&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cazorla-S&#225;nchez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hern&#225;ndez-Andreu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Galindo-Ortego</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Feasibility and Acceptability of Personalized Breast Cancer Screening (DECIDO Study): A Single-Arm Proof-of-Concept Trial</article-title><source>Int. J. Environ. Res. Public Health</source><year>2022</year><volume>19</volume><elocation-id>10426</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph191610426</pub-id><pub-id pub-id-type="pmid">36012059</pub-id><pub-id pub-id-type="pmcid">PMC9407798</pub-id></element-citation></ref><ref id="B46-jpm-14-00863"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brooks</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Nabi</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Andrulis</surname><given-names>I.L.</given-names></name><name name-style="western"><surname>Antoniou</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Chiquette</surname><given-names>J.</given-names></name><name name-style="western"><surname>Despr&#233;s</surname><given-names>P.</given-names></name><name name-style="western"><surname>Devilee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dorval</surname><given-names>M.</given-names></name><name name-style="western"><surname>Droit</surname><given-names>A.</given-names></name><name name-style="western"><surname>Easton</surname><given-names>D.F.</given-names></name><etal/></person-group><article-title>Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&amp;I)</article-title><source>J. Pers. Med.</source><year>2021</year><volume>11</volume><elocation-id>511</elocation-id><pub-id pub-id-type="doi">10.3390/jpm11060511</pub-id><pub-id pub-id-type="pmid">34199804</pub-id><pub-id pub-id-type="pmcid">PMC8226444</pub-id></element-citation></ref><ref id="B47-jpm-14-00863"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shah</surname><given-names>A.</given-names></name><name name-style="western"><surname>Polascik</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>George</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hyslop</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ellis</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Ferrandino</surname><given-names>M.</given-names></name><name name-style="western"><surname>Preminger</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.T.</given-names></name><etal/></person-group><article-title>Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network</article-title><source>J. Gen. Intern. Med.</source><year>2021</year><volume>36</volume><fpage>92</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1007/s11606-020-06124-2</pub-id><pub-id pub-id-type="pmid">32875501</pub-id><pub-id pub-id-type="pmcid">PMC7858708</pub-id></element-citation></ref><ref id="B48-jpm-14-00863"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rainey</surname><given-names>L.</given-names></name><name name-style="western"><surname>van der Waal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>L.S.</given-names></name><name name-style="western"><surname>Southworth</surname><given-names>J.</given-names></name><name name-style="western"><surname>French</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Evans</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Broeders</surname><given-names>M.J.M.</given-names></name></person-group><article-title>Women&#8217;s health behaviour change after receiving breast cancer risk estimates with tailored screening and prevention recommendations</article-title><source>BMC Cancer</source><year>2022</year><volume>22</volume><elocation-id>69</elocation-id><pub-id pub-id-type="doi">10.1186/s12885-022-09174-3</pub-id><pub-id pub-id-type="pmid">35033023</pub-id><pub-id pub-id-type="pmcid">PMC8761310</pub-id></element-citation></ref><ref id="B49-jpm-14-00863"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nash</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Menon</surname><given-names>U.</given-names></name></person-group><article-title>Ovarian cancer screening: Current status and future directions</article-title><source>Best Pract. Res. Clin. Obstet. Gynaecol.</source><year>2020</year><volume>65</volume><fpage>32</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.bpobgyn.2020.02.010</pub-id><pub-id pub-id-type="pmid">32273169</pub-id></element-citation></ref><ref id="B50-jpm-14-00863"><label>50.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>QIMR-Berghofer</collab></person-group><article-title>QSkin2</article-title><year>2023</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://publications.qimrberghofer.edu.au/Custom/QSkinMelanomaRisk" ext-link-type="uri">https://publications.qimrberghofer.edu.au/Custom/QSkinMelanomaRisk</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2023-08-30">(accessed on 30 August 2023)</date-in-citation></element-citation></ref><ref id="B51-jpm-14-00863"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vuong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Armstrong</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Weiderpass</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lund</surname><given-names>E.</given-names></name><name name-style="western"><surname>Adami</surname><given-names>H.-O.</given-names></name><name name-style="western"><surname>Veierod</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Whiteman</surname><given-names>D.C.</given-names></name><etal/></person-group><article-title>Development and External Validation of a Melanoma Risk Prediction Model Based on Self-assessed Risk Factors</article-title><source>JAMA Dermatol.</source><year>2016</year><volume>152</volume><fpage>889</fpage><lpage>896</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2016.0939</pub-id><pub-id pub-id-type="pmid">27276088</pub-id></element-citation></ref><ref id="B52-jpm-14-00863"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaiser</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pfahlberg</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Uter</surname><given-names>W.</given-names></name><name name-style="western"><surname>Heppt</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Veier&#248;d</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Gefeller</surname><given-names>O.</given-names></name></person-group><article-title>Risk Prediction Models for Melanoma: A Systematic Review on the Heterogeneity in Model Development and Validation</article-title><source>Int. J. Environ. Res. Public Health</source><year>2020</year><volume>17</volume><elocation-id>7919</elocation-id><pub-id pub-id-type="doi">10.3390/ijerph17217919</pub-id><pub-id pub-id-type="pmid">33126677</pub-id><pub-id pub-id-type="pmcid">PMC7662952</pub-id></element-citation></ref><ref id="B53-jpm-14-00863"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Usher-Smith</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Emery</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kassianos</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>F.M.</given-names></name></person-group><article-title>Risk prediction models for melanoma: A systematic review</article-title><source>Cancer Epidemiol. Biomark. Prev.</source><year>2014</year><volume>23</volume><fpage>1450</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-14-0295</pub-id><pub-id pub-id-type="pmid">24895414</pub-id></element-citation></ref><ref id="B54-jpm-14-00863"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashani-Sabet</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leachman</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Stein</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Arbiser</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Celebi</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Curiel-Lewandrowski</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Grant-Kels</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Grossman</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing</article-title><source>JAMA Dermatol.</source><year>2023</year><volume>159</volume><fpage>545</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1001/jamadermatol.2023.0127</pub-id><pub-id pub-id-type="pmid">36920356</pub-id><pub-id pub-id-type="pmcid">PMC11225588</pub-id></element-citation></ref><ref id="B55-jpm-14-00863"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Dite</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Spaeth</surname><given-names>E.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Allman</surname><given-names>R.</given-names></name></person-group><article-title>Melanoma risk prediction based on a polygenic risk score and clinical risk factors</article-title><source>Melanoma Res.</source><year>2023</year><volume>33</volume><fpage>293</fpage><lpage>299</lpage><pub-id pub-id-type="doi">10.1097/CMR.0000000000000896</pub-id><pub-id pub-id-type="pmid">37096571</pub-id><pub-id pub-id-type="pmcid">PMC10309112</pub-id></element-citation></ref><ref id="B56-jpm-14-00863"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>E Johns</surname><given-names>L.</given-names></name><name name-style="western"><surname>A Coleman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Swerdlow</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>S.M.</given-names></name></person-group><article-title>Effect of population breast screening on breast cancer mortality up to 2005 in England and Wales: An individual-level cohort study</article-title><source>Br. J. Cancer</source><year>2016</year><volume>116</volume><fpage>246</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/bjc.2016.415</pub-id><pub-id pub-id-type="pmid">27931047</pub-id><pub-id pub-id-type="pmcid">PMC5243996</pub-id></element-citation></ref><ref id="B57-jpm-14-00863"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Katalinic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eisemann</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kraywinkel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Noftz</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>H&#252;bner</surname><given-names>J.</given-names></name></person-group><article-title>Breast cancer incidence and mortality before and after implementation of the German mammography screening program</article-title><source>Int. J. Cancer</source><year>2020</year><volume>147</volume><fpage>709</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1002/ijc.32767</pub-id><pub-id pub-id-type="pmid">31675126</pub-id></element-citation></ref><ref id="B58-jpm-14-00863"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morrell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roder</surname><given-names>D.</given-names></name><name name-style="western"><surname>Robson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>M.</given-names></name><name name-style="western"><surname>Craig</surname><given-names>K.</given-names></name></person-group><article-title>Mammography service screening and breast cancer mortality in New Zealand: A National Cohort Study 1999&#8211;2011</article-title><source>Br. J. Cancer</source><year>2017</year><volume>116</volume><fpage>828</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1038/bjc.2017.6</pub-id><pub-id pub-id-type="pmid">28183141</pub-id><pub-id pub-id-type="pmcid">PMC5355933</pub-id></element-citation></ref><ref id="B59-jpm-14-00863"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sankatsing</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>van Ravesteyn</surname><given-names>N.T.</given-names></name><name name-style="western"><surname>Heijnsdijk</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Looman</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>van Luijt</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Fracheboud</surname><given-names>J.</given-names></name><name name-style="western"><surname>Heeten</surname><given-names>G.J.D.</given-names></name><name name-style="western"><surname>Broeders</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>de Koning</surname><given-names>H.J.</given-names></name></person-group><article-title>The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up</article-title><source>Int. J. Cancer</source><year>2017</year><volume>141</volume><fpage>671</fpage><lpage>677</lpage><pub-id pub-id-type="doi">10.1002/ijc.30754</pub-id><pub-id pub-id-type="pmid">28457023</pub-id></element-citation></ref><ref id="B60-jpm-14-00863"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Ourti</surname><given-names>T.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ko&#231;</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fracheboud</surname><given-names>J.</given-names></name><name name-style="western"><surname>de Koning</surname><given-names>H.J.</given-names></name></person-group><article-title>Effect of screening mammography on breast cancer mortality: Quasi-experimental evidence from rollout of the Dutch population-based program with 17-year follow-up of a cohort</article-title><source>Int. J. Cancer</source><year>2020</year><volume>146</volume><fpage>2201</fpage><lpage>2208</lpage><pub-id pub-id-type="doi">10.1002/ijc.32584</pub-id><pub-id pub-id-type="pmid">31330046</pub-id><pub-id pub-id-type="pmcid">PMC7065105</pub-id></element-citation></ref><ref id="B61-jpm-14-00863"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Etzioni</surname><given-names>R.</given-names></name><name name-style="western"><surname>Duggan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>B.O.</given-names></name></person-group><article-title>Demographic changes in breast cancer incidence, stage at diagnosis and age associated with population-based mammographic screening</article-title><source>J. Surg. Oncol.</source><year>2017</year><volume>115</volume><fpage>517</fpage><lpage>522</lpage><pub-id pub-id-type="pmid">28194807</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jso.24579</pub-id><pub-id pub-id-type="pmcid">PMC5701282</pub-id></element-citation></ref><ref id="B62-jpm-14-00863"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welch</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Mazer</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Adamson</surname><given-names>A.S.</given-names></name></person-group><article-title>The Rapid Rise in Cutaneous Melanoma Diagnoses</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>341</volume><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1056/NEJMsb2019760</pub-id><pub-id pub-id-type="pmid">33406334</pub-id></element-citation></ref><ref id="B63-jpm-14-00863"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adamson</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Naik</surname><given-names>G.</given-names></name><name name-style="western"><surname>A Jones</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>K.J.</given-names></name></person-group><article-title>Ecological study estimating melanoma overdiagnosis in the USA using the lifetime risk method</article-title><source>BMJ Evid.-Based Med.</source><year>2024</year><volume>29</volume><fpage>156</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1136/bmjebm-2023-112460</pub-id><pub-id pub-id-type="pmid">38242569</pub-id></element-citation></ref><ref id="B64-jpm-14-00863"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cust</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Baade</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Whiteman</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Soyer</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Janda</surname><given-names>M.</given-names></name></person-group><article-title>Why a randomized melanoma screening trial may be a good idea</article-title><source>Br. J. Dermatol.</source><year>2018</year><volume>179</volume><fpage>1227</fpage><pub-id pub-id-type="doi">10.1111/bjd.17089</pub-id><pub-id pub-id-type="pmid">30101459</pub-id></element-citation></ref><ref id="B65-jpm-14-00863"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halvorsen</surname><given-names>J.</given-names></name><name name-style="western"><surname>L&#248;berg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gjersvik</surname><given-names>P.</given-names></name><name name-style="western"><surname>Roscher</surname><given-names>I.</given-names></name><name name-style="western"><surname>Veier&#248;d</surname><given-names>M.</given-names></name><name name-style="western"><surname>Robsahm</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nilsen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kalager</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bretthauer</surname><given-names>M.</given-names></name></person-group><article-title>Why a randomized melanoma screening trial is not a good idea</article-title><source>Br. J. Dermatol.</source><year>2018</year><volume>179</volume><fpage>532</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1111/bjd.16784</pub-id><pub-id pub-id-type="pmid">29893490</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="jpm-14-00863-f001" orientation="portrait"><label>Figure 1</label><caption><p>Flowchart of selection of studies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jpm-14-00863-g001.jpg"/></fig><table-wrap position="float" id="jpm-14-00863-t001" orientation="portrait"><object-id pub-id-type="pii">jpm-14-00863-t001_Table 1</object-id><label>Table 1</label><caption><p>Key characteristics of Selected studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Cancer(s)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Author<break/>(Year)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Location</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Period</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Study Design</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Participants</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Risk Thresholds</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Screening Pathways</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sample</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Size</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brooks<break/>(2021) [<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Canada</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021&#8211;2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mixed-methods</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unaffected women;<break/>40&#8211;69 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5000</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10-year risk corresponding to remaining lifetime risk:<break/>Average: &lt;15%; <break/>Higher than average: 15&#8211;25%; <break/>High: &#8805;25%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Average:<break/>40&#8211;49 years: no regular screening with mammogram; <break/>50&#8211;69 years: screen with a mammogram/2 years.<break/>Higher than average:<break/>- Ontario<break/>40&#8211;49 years: screen with mammogram/year; <break/>50&#8211;69 years: screen with mammogram/year; <break/>- Quebec<break/>Screen with mammogram/1&#8211;2 years, ultrasound considered if breast density is &gt;75%;<break/>High:<break/>40&#8211;69 years: screen with mammogram and <sup>&#8224;</sup> MRI/year.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Esserman<break/>(2017) [<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016&#8211;2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">** RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unaffected women;<break/>40&#8211;74 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100,000</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5-y absolute risk: <break/>&lt;1.3%;<break/>1.3&#8211;6%;<break/>&#8805;6%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 years:<break/>Digital mammography/2 years;<break/>40&#8211;49 years: <break/>Screening is recommended when their 5-year risk equals or exceeds that of the average woman aged 50 years. Screen/2 year, except women with extremely dense breasts, who will be offered annual screening.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evans (2023) [<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">United Kingdom</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019&#8211;2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Non-RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Biologically female reach 60 years;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2472</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Below average risk: 10 years &lt; 2%;<break/>Average risk: 2% &#8804; 10 years &lt; 5%;<break/>Moderate risk: 5% &#8804; 10 years &lt; 8%;<break/>High risk: 10-years &#8805; 8%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No screening intervals specified; participants were followed at baseline, 3 months, and 6 months</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Laza-Vasquez<break/>(2022) [<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spain</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019&#8211;2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single-arm proof-of-concept study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women;<break/>40&#8211;50 years;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">387</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Absolute risk of breast cancer at 5 years:<break/>&lt;0.99%;<break/>0.99&#8211;1.16%;<break/>&gt;1.16%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#8211;44 years: <break/>&lt;0.99%&#8212;watch and wait; 0.99&#8211;1.16%&#8212;biennial; <break/>&gt;1.16%&#8212;annual. <break/>45&#8211;48 years: <break/>&lt;0.99%&#8212;watch and wait; 0.99&#8211;1.19%&#8212;biennial; <break/>&gt;1.19%&#8212;annual. <break/>49&#8211;50 years: <break/>&lt;0.8%&#8212;triennial; <break/>0.8&#8211;1.19%&#8212;biennial; <break/>&gt;1.19%&#8212;annual. <break/>40&#8211;50 years:<break/>&gt;6%: referral to hospital breast unit and or genetic counseling</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liu<break/>(2022) [<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Singapore</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women;<break/>35&#8211;59 years;<break/>No cancer history</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3500</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5-years absolute risk above 3% as a threshold</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Current national guidelines:<break/>35&#8211;39 years: no recommendation;<break/>40&#8211;49 years: mammography screening/year;<break/>50&#8211;59 years: mammography screening/2 years;<break/>In this study, women identified to be above average in breast cancer risk are referred to breast specialists at designated study sites, in addition to prevailing guidelines.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rainey<break/>(2022) [<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">United Kingdom</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014&#8211;2019</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Focus group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unaffected women;<break/>50&#8211;70 years;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">325</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10-year risk:<break/>Low risk: &#8804;1.5%;<break/>Average risk: 1.5&#8211;4.99%;<break/>Moderate risk: 5&#8211;7.99%;<break/>High risk: &#8805;8%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low risk: screening/3 years;<break/>Average risk: screening/3 years;<break/>Moderate risk: screening/3 years; <break/>High risk: screening/18 m</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yen<break/>(2016) [<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Taiwan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1999&#8211;2009</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cohort study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Asymptomatic women; <break/>40&#8211;69 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1,429,890</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High risk:<break/>risk scores &gt; median value of the underlying population</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single screening method:<break/>1 clinical breast examination (CBE); <break/>1 risk-based mammography; <break/>1 universal mammography;<break/>2 screening methods: <break/>Risk-based and universal mammography;<break/>CBE and universal mammography;<break/>CBE and risk-based mammography;<break/>3 screening methods:<break/>Risk-based + universal mammography + CBE.</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Colorectal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chen<break/>(2023) [<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">China</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018&#8211;2021</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">** RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unaffected; <break/>50&#8211;74 years;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19,373</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5-year risk:<break/>Low-risk: APCS &lt; 4;<break/>High-risk: APCS &#8805; 4</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Arm 1 (<italic toggle="yes">n</italic> = 3883): 1-time colonoscopy;<break/>Arm 2 (<italic toggle="yes">n</italic> = 7793): annual <sup>&#8224;&#8224;</sup> FIT;<break/>Arm 3 (<italic toggle="yes">n</italic> = 7697):<list list-type="simple"><list-item><label>-</label><p>Low: <sup>&#8224;&#8224;</sup> FIT/year for 3 years;</p></list-item><list-item><label>-</label><p>High: colonoscopy/year for 3 years.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emery<break/>(2023) [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Australia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017&#8211;2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">** RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#8211;74 years;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">734</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intervention group determined by CRISP-calculated 5-year CRC risk:<break/>2.5% as threshold from biennial FOBT testing to 5-yearly colonoscopy;<break/>Control group determined by family history in accordance with the NHMRC-endorsed guidelines</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">At baseline, 1, 6, and 12 months post-randomization.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saya<break/>(2022) [<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Australia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2022</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">** RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45&#8211;70 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">274</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10-years risk:<break/>&lt;1%;<break/>1&#8211;4%;<break/>&#8805;4%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk &lt;1%: no screening recommended;<break/>Risk 1&#8211;4%: iFOBT<break/>Risk &#8805;4%: colonoscopy.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Schroy<break/>(2016) [<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012&#8211;2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">** RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#8211;75 years;<break/>due for CRC screening in an urban safety net Hhealthcare setting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">352</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low risk: cumulative scores &lt;5;<break/>Intermediate/high risk: cumulative scores: 6&#8211;12;</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No screening intervals specified.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trevena (2022) [<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Australia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012&#8211;2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cluster RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25&#8211;74 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1495</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lifetime risk:<break/>At or slightly above average risk;<break/>Moderately increased risk;<break/>Potentially high risk.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">At or slightly above average risk:<break/>&#8805;50 years&#8212;FOBT/2 years; <break/>Moderately increased risk:<break/>1 colonoscopy in past 5 years if &gt;50 years old, or if older than 10 years, earlier than youngest bowel cancer diagnosis in first-degree relatives. <break/>Potentially high risk: assessment by familial cancer service (or similar) OR colonoscopy at a frequency consistent with family history (as assessed by a panel of clinicians).</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prostate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Freds&#248;e<break/>(2020) [<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Denmark</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013&#8211;2014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cluster RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Men;<break/>18&#8211;80 years;<break/>Normal PSA test result<break/>(normal PSA:<break/>&lt;3.0 ng/mL for men below<break/>age 60;<break/>&lt;4.0 ng/mL for men aged 60&#8211;70;<break/>&lt;5.0 ng/mL for men aged &#8805;70)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5000<break/>(actual number registered at clinicaltrials.gov)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lifetime risk:<break/>High risk: &#8805;30%<break/>Normal risk: &lt;30%<break/>Unknown risk: cannot be estimated due to missing information for family history</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No screening intervals specified; participants were followed at 2 years.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shah<break/>(2021) [<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">United States</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016&#8211;2018</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-post study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Men;<break/>40&#8211;75 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre: 49,053; <break/>Post: 49,980</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High risk:<break/>African-Americans, with family history of prostate cancer/abnormal genetic evaluation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40&#8211;49 years: <break/>PSA &#8805; 1.5 ng/mL&#8212;refer to multidisciplinary prostate screening clinic; <break/>PSA &lt; 1.5 ng/mL and high risk&#8212;screen/2 years; <break/>PSA &lt; 1.5 ng/mL and average risk&#8212;resume screening at age 50; <break/>50&#8211;69 years: <break/>PSA &lt; 3 ng/mL&#8212;screen/2 years; PSA &#8805; 3 ng/mL&#8212;refer to multidisciplinary prostate screening clinic; <break/>70&#8211;75 years: <break/>PSA &#8804; 6.5 ng/mL&#8212;refer to multidisciplinary prostate screening clinic; <break/>PSA &gt; 6.5 ng/mL&#8212;screen/2 years.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Field<break/>(2015) [<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">United Kingdom</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">** RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50&#8211;75 years;<break/>5-year lung cancer risk of &#8805;5% based on the LLPv2 risk prediction model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4055</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LLPv<sub>2</sub> risk prediction model selects subjects with &#8805;5% risk of developing lung cancer in 5 years</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<list list-type="simple"><list-item><label>-</label><p>No nodules or category 1 (benign) nodules: no further action required;</p></list-item><list-item><label>-</label><p>Category 2 (small, probably benign) nodules: follow-up CT;</p></list-item><list-item><label>-</label><p>Category 3 (larger, potentially malignant) nodules: follow-up CT scan at 3 months and 12 months;</p></list-item><list-item><label>-</label><p>Category 4 (higher chance of malignancy) nodules: immediate referral to multidisciplinary team (MDT);</p></list-item><list-item><label>-</label><p>Nodules &gt; 500 mm<sup>3</sup> or 10 mm maximum diameter at baseline (category 4) or nodules that demonstrated growth on follow-up CT (as defined by a volume doubling time &lt;400 days) were referred to the local MDT for further assessment.</p></list-item></list>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovary</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gaba<break/>(2020) [<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">United Kingdom</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2017</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Feasibility</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Women;<break/>&#8805;18 years;<break/>No ovarian/tubal/primary peritoneal cancer or ovarian cancer susceptibility genes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lifetime risk:<break/>Low risk: &lt;5%; <break/>Intermediate risk: 5&#8211;10%; <break/>High risk: &#8805;10%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No screening intervals specified;</td></tr></tbody></table><table-wrap-foot><fn><p>** RCT: randomized controlled trial; <sup>&#8224;</sup> MRI: magnetic resonance imaging; <sup>&#8224;&#8224;</sup> FIT: fecal immunochemical test.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jpm-14-00863-t002" orientation="portrait"><object-id pub-id-type="pii">jpm-14-00863-t002_Table 2</object-id><label>Table 2</label><caption><p>A summary of the risk assessment approaches employed in the selected studies (by cancer type).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer (s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author (Year)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Questionnaire</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Imaging, Blood, or Saliva Test</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Polygenic Score</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Model</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Combinations</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brooks (2021) [<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>(Mammographic density)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Single-nucleotide polymorphisms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>BOADICEA model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Esserman (2017) [<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Breast Cancer Surveillance Consortium (BCSC) model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evans (2023) [<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>(Mammographic density)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Single-nucleotide polymorphisms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Tyrer&#8211;Cuzick risk model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Laza-Vasquez (2022) [<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>(Mammographic density)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Single-nucleotide polymorphisms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Breast Cancer Surveillance Consortium (BCSC) model V2.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liu (2022) [<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>(Mammographic density)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Single-nucleotide polymorphisms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>BOADICEA model Gail model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rainey (2022) [<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>(Mammographic density)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Single-nucleotide polymorphisms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Tyrer&#8211;<break/>Cuzick (TC) risk prediction model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yen (2016) [<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Colorectal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chen (2023) [<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>[Asia-Pacific Colorectal Screening (APCS) score]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emery (2023) [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>[Colorectal cancer RISk Prediction (CRISP) risk tool]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saya (2022) [<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Single-nucleotide polymorphisms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Schroy (2016) [<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>(6-item risk assessment tool)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trevena (2022) [<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>[Colorectal cancer (CRC risk calculator)]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prostate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Freds&#248;e (2020) [<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>(PSA test)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Single-nucleotide polymorphisms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shah (2021) [<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>(PSA test)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Field (2015) [<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>[Computed tomography (CT) scan]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>LLPv<sub>2</sub> risk prediction model</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovary</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gaba (2020) [<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">X</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>Single-nucleotide polymorphisms</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;<break/>(Epidemiological/hormonal/reproductive data combined with genetic information)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#10003;</td></tr></tbody></table><table-wrap-foot><fn><p>&#10003;: if a certain approach was incorporated; X: if a certain approach was not incorporated.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jpm-14-00863-t003" orientation="portrait"><object-id pub-id-type="pii">jpm-14-00863-t003_Table 3</object-id><label>Table 3</label><caption><p>Summary of risk thresholds and screening pathways (by cancer type).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer (s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Author (Year)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Risk Thresholds</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Screening Pathway</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brooks (2021) [<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 risk categories based on 10-year/remaining lifetime risk</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 pathways based on 2 age categories and 3 risk levels</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Esserman (2017) [<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 risk categories based on 5-year risk</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 pathways based on age, risk levels and breast density</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evans (2023) [<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No screening intervals specified; participants were followed at baseline, 3 months, and 6 months</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Laza-Vasquez (2022) [<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 groups based on age and risk levels</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liu (2022) [<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 groups based on age and risk threshold levels</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rainey (2022) [<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 groups based on age and risk threshold levels</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yen (2016) [<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 groups based on risk threshold levels</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Colorectal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chen (2023) [<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 groups based on risk threshold levels</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Emery (2023) [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 groups based on risk threshold levels</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Saya (2022) [<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 groups based on risk threshold levels</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Schroy (2016) [<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No screening intervals specified</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trevena (2022) [<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 groups based on age, family history of cancer, and risk threshold levels</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prostate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Freds&#248;e (2020) [<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No screening intervals specified; participants were followed at 2-year</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Shah (2021) [<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 groups based on age, PSA levels, and risk threshold levels</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Field (2015) [<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 groups based on nodule classifications</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovary</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gaba (2020) [<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 risk categories</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No screening intervals specified</td></tr></tbody></table></table-wrap><table-wrap position="float" id="jpm-14-00863-t004" orientation="portrait"><object-id pub-id-type="pii">jpm-14-00863-t004_Table 4</object-id><label>Table 4</label><caption><p>Key components of screening studies (by cancer type).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Name<break/>(Registration No.)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Primary Outcome</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Measurements</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Results</th></tr></thead><tbody><tr><td rowspan="10" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PERSPECTIVE I&amp;I <sup>1</sup><break/>(Not found)<break/>[<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acceptability and feasibility of risk-based screening, uptake of genetic testing for risk assessment and screening behaviors.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Identification of new predisposition genes;<break/>Assessment of different recruitment and data-collection strategies using questionnaires;<break/>Assessment of acceptability and healthcare system readiness through survey and online forums;<break/>Economic analysis using administrative data.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not yet available.<break/></td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">WISDOM<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT02620852">NCT02620852</ext-link>) <break/>[<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Safety<break/>(non-inferiority).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rate of stage IIB cancers or higher diagnosed in annual vs. risk-based screening arms.</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Not yet available<break/>(estimated completed date: 1 December 2024).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Morbidity.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rate of recall and breast biopsy between arms.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BC-Predict<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04359420">NCT04359420</ext-link>) <break/>[<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Feasibility.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Screening attendance at or within 180 days of the initial screening appointment;<break/>Uptake to BC-Predict of those attending screening;<break/>Time to provision of risk feedback letter and proportion over 8-week threshold;<break/>Subsequent consultation in clinics (telephone, as face-to-face not possible);<break/>Subsequent enrolment for more frequent mammography (NICE approved through clinics to age 60 or self-funded outside);<break/>Subsequent prescription of breast-cancer-preventive-medication.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Overall uptake of BC-Predict in screening attendees was 16.9%; 76.8% of those received risk feedback within the 8-week timeframe.</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">DECIDO<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03791008">NCT03791008</ext-link>) <break/>[<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Attitude towards personalized breast cancer screening.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Attitude was measured with a three-item scale, each item ranging from 1 to 5,<break/>with higher scores indicating more positive attitudes. <break/>A &#8220;positive attitude&#8221; was defined<break/>as a total score greater than or equal to 12.</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">High positive attitude score towards personalized screening, with a median of 12.<break/>2 out of 3 women scored &gt; 12 indicting positive attitudes towards personalized screening;<break/>The intention to participate in personalized breast screening rated as &#8220;definitely will&#8221; or &#8220;likely to&#8221; by 9 out of 10 women;<break/>97% of the women declared satisfied/very satisfied with<break/>personalized breast screening; 2.6% were not sure; <break/>1 was very unsatisfied.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intention to participate in personalized breast cancer screening.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intention to participate was measured with a 5-point Likert scale from definitely will (1) to definitely will not (5).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Satisfaction with personalized breast cancer screening.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Satisfaction was measured on a 5-point Likert scale from very unsatisfied to very satisfied.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BREATHE<break/>(Not found) <sup>2</sup><break/>[<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acceptability, willingness, and cost-effectiveness.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Satisfaction survey</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not yet available.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PROCAS<break/>(ISRCTN91372184) <break/>[<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Key factors in participants&#8217; adoption of screening and prevention recommendations after cancer risk communication.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early detection behaviors: <list list-type="simple"><list-item><label>-</label><p>Intent to request supplemental mammography outside the national screening programme (yes vs. no or do not know; for average and moderate risk groups);</p></list-item><list-item><label>-</label><p>Increased breast self-examination (yes vs. no).</p></list-item></list>Preventive behaviors: <list list-type="simple"><list-item><label>-</label><p>Started with preventative medication (yes vs. no; for moderate and high-risk groups);</p></list-item><list-item><label>-</label><p>Changed diet (yes vs. no);</p></list-item><list-item><label>-</label><p>Changed physical activity levels (yes vs. no);</p></list-item><list-item><label>-</label><p>Changed alcohol intake (yes vs. no).</p></list-item></list></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Predictors of intent to request supplemental mammography outside the national screening program includes the following:<list list-type="simple"><list-item><label>-</label><p>Supplemental screening and breast self-examination;</p></list-item><list-item><label>-</label><p>Risk-reducing medication;</p></list-item><list-item><label>-</label><p>Preventive lifestyle behaviors;</p></list-item><list-item><label>-</label><p>Having a first degree relative with breast cancer;</p></list-item><list-item><label>-</label><p>Higher age;</p></list-item><list-item><label>-</label><p>Higher body mass index.</p></list-item></list></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not found <sup>3</sup><break/>[<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effectiveness</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detection (diagnosis) rates;<break/>Stage II+ disease incidence;<break/>Mortality from breast cancer;<break/>Overdiagnosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cancer detection rates were highest for universal biennial mammography (4.9% and 3.0%, respectively), followed by<break/>risk-based mammography (2.8% and 2.8%, respectively), and lowest for annual CBE (0.97% and 0.70%, respectively). <break/>Universal biennial mammography screening, compared with annual CBE, was associated with a 41% mortality reduction (*** RR = 0.59; 95%CI, 0.48&#8211;0.73) and a 30% reduction in stage II+ breast cancer (*** RR = 0.70; 95%CI, 0.66&#8211;0.74). <break/>Risk-based mammography screening was associated with an 8%reduction in stage II+ breast cancer (*** RR = 0.92; 95%CI,<break/>0.86&#8211;0.99) but was not associated with a statistically significant mortality reduction (*** RR = 0.86; 95%CI, 0.73&#8211;1.02). Estimates of overdiagnosis were no different from CBE for risk-based screening and 13% higher than CBE for universal mammography.</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Colorectal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TARGET-C<break/>(ChiCTR1800015506) [<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detection rate of<break/>advanced colorectal neoplasms (CRC and advanced precancerous<break/>lesions)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Advanced adenoma was defined as adenoma with at least 1 of the following features: <list list-type="simple"><list-item><label>-</label><p>High-grade dysplasia,</p></list-item><list-item><label>-</label><p>Villous or tubulovillous histologic features</p></list-item><list-item><label>-</label><p>Size &#8805; 10 mm.</p></list-item></list>Advanced serrated adenoma was defined as any serrated adenoma (traditional serrated adenoma or sessile serrated lesion) &#8805;10 mm or dysplasia;<break/>Both advanced adenoma and advanced serrated lesions were regarded as advanced precancerous lesions.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colonoscopy (Arm 1): 2.76%<break/>* FIT (Arm 2): 2.17%<break/>Risk-adapted (Arm 3): 2.35%<break/>** OR <sub>colonoscopy vs. FIT</sub> = 1.27 <break/>(95% CI: 0.99&#8211;1.63)<break/>** OR <sub>colonoscopy vs. risk-adapted</sub> = 1.17 <break/>(95% CI:0.91&#8211;1.49)<break/>** OR <sub>risk-adapted vs. FIT</sub> = 1.09 <break/>(95% CI:0.88&#8211;1.35)<break/>Numbers of colonoscopies to detect 1 advanced neoplasm: 15.4, 7.8, and 10.2, respectively</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRISP<break/>(ACTRN12616001573448) [<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proportion of participants who completed risk-appropriate CRC screening at 12-month follow-up</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Screening participation rate was obtained from: <break/>Self-report; <break/>GP record audit; <break/>Medicare Benefits Schedule; <break/>NBCSP;<break/>Victorian Admitted Episodes Dataset (VAED).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intervention vs. Control:<break/>6.5% absolute increase <break/>(95%CI: &#8211;0.28&#8211;13.2);<break/>20.3% increase in those due CRC screening during follow-up<break/>(95%CI: 10.3&#8211;30.4)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCRIPT<break/>(ACTRN12621000092897p) [<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Impact of the<break/>SCRIPT intervention on risk-appropriate CRC screening after 12 months.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Difference between intervention and<break/>control arms in the proportion of participants who have had risk appropriate CRC screening at 12 months.<break/>follow-up.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not available</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01596582">NCT01596582</ext-link><break/>[<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concordance between patient preference<break/>and test ordered.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tracked using BMC&#8217;s electronic medical record ordering system.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No significant differences in concordance were observed.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACTRN12611000534987<break/>[<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk Appropriate<break/>Screening (RAS) and colorectal cancer screening uptake.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Through online CRC patient survey (24 screening and 9 patient demographic items).</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The intervention significantly increased RAS in high-risk participants compared with UCG (80.0% vs. 64.0%, respectively; OR = 3.14, 95% CI: 1.25&#8211;7.96) but not in average-risk (44.9% vs. 49.5%, respectively; OR = 0.97, 95% CI: 0.99&#8211;1.12) or moderate-risk individuals (67.9% vs. 81.1%, respectively; OR = 0.40, 95% CI: 0.12&#8211;1.33).</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prostate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ProCaRis<break/>(<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01739062">NCT01739062</ext-link>) <break/>[<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proportion of men having a repeated<break/>PSA test within 2 years.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proportion of men having a repeated<break/>PSA test within 2 years.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">At 2 years after inclusion, a total of 1218 men (34.2%) in the intervention practices and 1628 (38.4%) men in the control practices had a PSA test (OR = 0.95, 95% CI 0.78&#8211;1.14, <italic toggle="yes">p</italic> = 0.56);<break/>Men of high genetic risk had a higher propensity for repeated PSA testing within 2 years than men of normal genetic risk (** OR = 8.94, <italic toggle="yes">p</italic> &lt; 0.01).</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not found <sup>4</sup><break/>[<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Evaluate the implementation of a risk-based prostate-cancer-screening algorithm.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Percent of men who met screening algorithm criteria; <break/>Percent of men with a PSA result.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Percent of men who met screening algorithm criteria:<break/>49.3% (pre-implementation) vs. 68.0% (post-implementation) (<italic toggle="yes">p</italic> &lt; 0.001);<break/>Total number of men with abnormal PSA: <break/>Pre-implementation <italic toggle="yes">n</italic> = 366, 2.7%; Post-implementation <italic toggle="yes">n</italic> = 583, 4.9%.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UKLS<break/>(ISRCTN 78513845) <break/>[<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effectiveness of risk prediction modeling;<break/>Evaluation of volumetric analysis in the management of CT-detected nodules; <break/>Cost-effectiveness.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Population-based recruitment based on risk stratification;<break/>Study management through a web-based database;<break/>Define optimal characteristics of CT readers (radiologists vs. radiographers);<break/>Characterization of CT-detected nodules utilizing volumetric analysis;<break/>Prevalence of lung cancer at baseline;<break/>Socio-demographic factors affecting participation;<break/>Psychosocial measures;<break/>Cost-effectiveness modeling.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">In total, 42 participants (2.1%) had confirmed lung cancer, 34 (1.7%) at baseline and 8 (0.4%) at the 12-month scan;<list list-type="simple"><list-item><label>-</label><p>28/42 (66.7%) had stage I disease</p></list-item><list-item><label>-</label><p>36/42 (85.7%) had stage I or II disease</p></list-item><list-item><label>-</label><p>35/42 (83.3%) had surgical resection</p></list-item></list>In total, 536 subjects had nodules greater than 50 mm<sup>3</sup> or 5 mm diameter <list list-type="simple"><list-item><label>-</label><p>41/536 were found to have lung cancer.</p></list-item><list-item><label>-</label><p>1 further cancer was detected by follow-up of nodules between 15 and 50 mm<sup>3</sup> at 12 months.</p></list-item></list>The baseline estimate for the incremental cost-effectiveness ratio of once-only CT screening, under the UKLS protocol, was &#163;8466 per quality adjusted life year gained (CI &#163;5542 to &#163;12,569).</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Ovary</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">PROMISE-FS<break/>(ISRCTN54246466) <break/>[<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Acceptability.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Responses to the decision aid questions and overall score.</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Decision aid satisfaction: 92.2%; Telephone helpline use rate:13%<break/>Questionnaire response rate at six months: 75%.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uptake of the study.</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Number of individuals who express interest in participating in the study (by post/email/telephone).</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Reason for non-registration: This is a pre-implementation project rather than a clinical trial; <sup>2</sup> Reason for non-registration: This is a study testing personalized risk assessment rather than a clinical trial; <sup>3</sup> Reason for non-registration: This is a population-based analysis rather than a clinical trial; <sup>4</sup> Reason for non-registration: This is a quality improvement intervention rather than a clinical trial. * FIT: Fecal immunochemical test; ** OR: Odds ratio; *** RR: Risk ratio.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="jpm-14-00863-t005" orientation="portrait"><object-id pub-id-type="pii">jpm-14-00863-t005_Table 5</object-id><label>Table 5</label><caption><p>Benefits&#8211;harm aummary for screening studies (by cancer type).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Cancer (s)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Study Name/No.</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Benefits</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Harms</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Benefit-Harm Assessment</th></tr></thead><tbody><tr><td rowspan="7" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Breast</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PERSPECTIVE I&amp;I <sup>1</sup><break/>[<xref rid="B46-jpm-14-00863" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not available</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not available</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not available</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WISDOM<break/>[<xref rid="B38-jpm-14-00863" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not available<break/>(estimated primary completed date: <break/>1 December 2024)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not available<break/>(estimated primary completed date: <break/>1 December 2024)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not available<break/>(estimated completed date: <break/>1 December 2024)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BC-Predict<break/>[<xref rid="B43-jpm-14-00863" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Risk stratification can be performed as part of routine NHS Breast Screening Programme delivery and supports the uptake of preventive medicines for women at high risk.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No evidence of adverse<break/>effects on anxiety beyond transient cancer worry;<break/>The practice of delivering risk-based screening was much less burdensome than healthcare professionals anticipated prior to<break/>Delivery.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Measures to increase uptake should be addressed, especially among women from lower socioeconomic and ethnic minority backgrounds.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DECIDO<break/>[<xref rid="B45-jpm-14-00863" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Positive attitude towards personalized breast screening;<break/>expressed strong intention to participate;<break/>and very satisfied with having participated in the study.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Knowledge of the benefits and harms of breast screening was low, especially with regard to false positives and overdiagnosis.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Demonstrates the need to create tools and strategies for developing interventions that focus on raising awareness about personalized screening and increasing literacy in risk measurement.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BREATHE <sup>2</sup><break/>[<xref rid="B41-jpm-14-00863" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only the study protocol is available.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only the study protocol is available.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only the study protocol is available.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PROCAS<break/>[<xref rid="B48-jpm-14-00863" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Breast cancer risk communication predicts the uptake of key tailored primary and secondary preventive<break/>Behaviors.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Effective communication of breast cancer risk information is essential to optimize the population wide impact of tailored screening.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not found <sup>3</sup><break/>[<xref rid="B42-jpm-14-00863" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compared with population-based screening for breast cancer with annual CBE, universal biennial mammography resulted in a substantial reduction in breast cancer deaths, whereas risk-based biennial mammography resulted in only a modest benefit.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Compared with annual CBE, risk-based and universal mammography screening did not result in significant overdiagnosis of breast cancer.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The findings should be informative to health policymakers seeking to determine if and how they might initiate breast-cancer-screening programs.</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Colorectal</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TARGET-C<break/>[<xref rid="B34-jpm-14-00863" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The risk-adapted approach saved 33% of endoscopy resources required for detecting 1 advanced neoplasm compared with the 1-time colonoscopy screening.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Costs for detecting 1 advanced neoplasm from the societal perspective were higher in the risk-adapted screening compared with the 1-time colonoscopy screening.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The risk-adapted approach is a feasible and cost-effective strategy for population-based CRC screening;<break/>The need for additional screening after 3 rounds or an expansion the screening interval should be addressed in future studies.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CRISP<break/>[<xref rid="B11-jpm-14-00863" ref-type="bibr">11</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A risk assessment and decision support tool increase risk-appropriate CRC screening in those due screening.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">There were no differences between groups at any timepoint on general or cancer-specific anxiety or absolute risk perception.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SCRIPT<break/>[<xref rid="B40-jpm-14-00863" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only the study protocol is available.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only the study protocol is available.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only the study protocol is available.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01596582">NCT01596582</ext-link><break/>[<xref rid="B35-jpm-14-00863" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Concordance was positively associated with satisfaction with the decision-making process, screening intentions, and test completion rates.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Providers perceived risk stratification to be useful in their decision-making but often failed to comply with patient preferences for tests other than colonoscopy.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ACTRN12611000534987<break/>[<xref rid="B39-jpm-14-00863" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Online CRC risk calculator increased risk appropriate screening in high-risk participants and improved screening uptake overall within a 12 m follow-up period.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Harms and costs of more invasive screening tests such as colonoscopy in lower risk individuals.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Online CRC risk calculator may be useful for facilitating the uptake of risk-based screening guidelines.</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Prostate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ProCaRis<break/>[<xref rid="B36-jpm-14-00863" ref-type="bibr">36</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Among participants who had a genetic test, knowledge of genetic risk significantly influenced future PSA testing.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Genetic test to assess lifetime risk of prostate cancer did not reduce the overall number of future PSA test.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The follow-up period of 2 years was not long enough to draw final conclusions about the effect of this intervention on the diagnosis or mortality rate of prostate cancer.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not found <sup>4</sup><break/>[<xref rid="B47-jpm-14-00863" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The adjusted odds of meeting algorithm-based screening was 6.5 times higher in the post-implementation period than in the pre-implementation period.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not reported</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An increase in screening in higher-risk groups balanced with a decrease in screening in low-risk groups.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">UKLS<break/>[<xref rid="B37-jpm-14-00863" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">It is possible to detect lung cancer at an early stage and deliver potentially curative treatment in over 80% of cases;<break/>Health economic analysis suggests that the intervention would be cost effective.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">False-positive rate: 3.6%<break/>Interval imaging rate: 23.2%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CT screening in the United Kingdom is possible using a risk prediction model that avoids the selection of people at very low risk who are unlikely to benefit, and a nodule management algorithm that effectively manages indeterminate CT findings, yet detects a high number of early-stage lung cancers.</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ovary</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PROMISE-FS<break/>[<xref rid="B44-jpm-14-00863" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">85.5&#8211;98.7% were satisfied with their decisions;<break/>Ovarian cancer related worry (<italic toggle="yes">p</italic> = 0.021) and general cancer risk perception (<italic toggle="yes">p</italic> = 0.015) decreased over 6 months.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">There were no significant effects on overall depression (<italic toggle="yes">p</italic> = 0.30), anxiety (<italic toggle="yes">p</italic> = 0.10), quality of life (<italic toggle="yes">p</italic> = 0.99), or distress level (<italic toggle="yes">p</italic> = 0.26).</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Population-based personalized ovarian cancer risk stratification is feasible and acceptable, has high satisfaction, reduces cancer worry/risk perception, and does not negatively impact psychological health/quality of life.</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Reason for non-registration: This is a pre-implementation project rather than a clinical trial; <sup>2</sup> Reason for non-registration: This is a study testing personalized risk assessment rather than a clinical trial; <sup>3</sup> Reason for non-registration: This is a population-based analysis rather than a clinical trial; <sup>4</sup> Reason for non-registration: This is a quality improvement intervention rather than a clinical trial.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>